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CHAPTER 1
THE ROLE OF NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
1.1 Introduction to Leukemia
Cancer is the number one cause of death from disease for American children. The
most common type of pediatric cancer is leukemia, accounting for nearly 1/3 of all cancer
cases.

Leukemia generally describes the clonal proliferation and accumulation of

malignant blast cells in the bone marrow and peripheral blood and is often associated
with chromosomal abnormalities and genetic mutations. Leukemia can arise in either the
myeloid or lymphoid lineages.

Regardless of the origins, the disease is generally

classified into two categories, either acute or chronic. Chronic leukemia is the excessive
accumulation of fairly mature but abnormal cells, which may take months to years for
progression. Acute leukemia is the rapid growth of immature cells with low levels of
differentiation.
Although the direct cause of leukemia in children is unknown, some studies
suggest that leukemia may be a consequence of in utero exposures to ionizing radiation,
pesticides and/or solvents1. There is a higher frequency of pediatric leukemia in Down
Syndrome, Bloom Syndrome, Neurofibromatosis type I and Ataxia-telangiectasis
patients2, 3. Evidence also suggests that leukemia arises more frequently in Caucasian
children, and in those from more affluent societies and urban areas, suggesting that some
socioeconomic factors may play a role in the etiology of the disease4-6. Inherited genetic
alterations in drug metabolism, DNA repair and cell-cycle checkpoints are thought to
interact with environmental, dietary, maternal and other factors to influence the
development and progression of leukemia, as well as its response to chemotherapy7-9.
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While leukemia (both acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL)) was the leading cause of cancer death in children in both 1975 and
2006, the percentage of death due to leukemia has decreased from 38.9% (1975) to
30.4% (2006)1.

Despite this decrease in death, the overall incidence of pediatric

lymphoid leukemia has increased significantly, with an annual percentage change of
0.8%1. The reason for this increase is unknown, however there are several hypotheses
exploring the relationships between pediatric leukemic risk and delayed exposure to
infectious agents, as well as the relationship to birth weight1, 10-13. Despite this alarming
increase in incidence rate, the mortality rate for pediatric leukemia has decreased by
nearly 64% between 1975 and 20061. This is evident by increases in 5-year survival
rates, from 61% during 1975-1978 to nearly 88.5% during 1999-2006 in children younger
than 15 years old. Similar improvements are seen in adolescents and young adults (15-19
years old), but their 5-year survival rate was only 50.1% during 1999-20061. This lag in
survival improvement is thought to be due to differences in tumor biology and overall
treatment between these two age groups14, 15. Adolescents and young adults with ALL
typically have more prognostically poorer disease characteristics, including advance age
and T-cell ALL HOX abnormalities16,17 (see below).

However, it is believed that

treatment has more of an impact on the difference in disease survival between pediatric
and adult T-ALL patients than the underlying difference in disease characteristics17.
Children under the age of 15 are usually treated with pediatric protocols, while older
adolescents may be treated with either pediatric protocols or adult protocols depending
upon their physician. Adult ALL patients face an even worse prognosis. With modern
therapies, adults have a long term disease-free survival rate of only 40%16. As mentioned
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above, the discrepancy in survival rate for children, adolescents and adults may be due to
biological differences in the disease at these life stages, as well as the types of therapies
administered.

That is, children under the age of 10 tend to have more favorable

prognostic indicators than adolescents and adults15. Treatment protocols for adolescents
and young adults have been shown to be far more inferior to pediatric protocols17.
1.2 Classification of ALL
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with diverse
morphologic, immunologic and genetic features. Immunophenotypically unique ALL
subgroups exhibit characteristic biochemical, clinical and cytogenetic features that are
typically associated with different prognoses18-21. B-cell ALL (B-ALL) accounts for up
to 80% of ALL cases. It arises in both precursor (BP) and mature B-cells. Nearly 80%
of pediatric BP-ALL patients experience long-term survival (>5 years) with modern
therapies19-21. B-ALL is usually accompanied by chromosomal abnormalities, which play
a key role in the development of the disease. These abnormalities serve as biomarkers
which are used to predict prognosis and determine the most optimal therapeutic regimen.
Acquired chromosomal abnormalities occur in ~90% of pediatric ALLs and nearly 2/3 of
these are directly relevant to prognosis18,

20, 21

. Hyperdiploidy (>50 chromosomes) is

found in ~25% of BP-ALL cases and is a good prognostic indicator for children treated
with antimetabolite-based therapy18, 20, 21. Chromosomal structural alterations frequently
involve balanced or reciprocal translocations leading to recombination of gene loci and
deregulated expression of proto-oncogenes or expression of fusion proteins with
properties distinct from their wild-type counterparts. These gene fusions frequently lead
to the constitutive activation of kinases [e.g., BCR-ABL in t(9;22)] or altered
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transcriptional regulation [e.g., MLL in t(4;11); AML1 or TEL in t(12;21)] that are either
initiating events in leukemogenesis or greatly influence the chemotherapeutic response18.
T-cell ALL (T-ALL) is an aggressive and malignant disease of thymocytes22, and
accounts for nearly 15% of pediatric ALLs and nearly 25% of adult ALL cases21, 23. It
arises in the thymus and can quickly spread through out the entire body. The prognosis
of T-ALL has improved in that nearly 80% of children and 50% of adults are now cured
with aggressive multi-agent therapies and is quickly approaching cure rates for BPALL20, 21, 24. However, long-term survival rates for pediatric T-ALL still lag behind those
for BP-ALL by up to 20%20, 21, 24, and such aggressive treatment has numerous late-in-life
effects, including secondary cancers. Relapse is a very common feature of T-ALL and is
one of the reasons why this subtype of ALL has an inferior clinical outcome. Relapse
typically occurs in about 30% of childhood and 50% of adult T-ALL cases25. Relapses
are the result of outgrowth of residual leukemic cells that were present below the limit of
detection following induction therapy.

This outgrowth can arise from the original

diagnostic leukemic clone that acquired genetic abnormalities that promoted
chemoresistance, or may be an entirely different clone that was already predisposed to be
chemoresistant26-28. Regardless of how relapses occur, the prognosis of T-ALL patients
with primary resistant or relapsed disease is very poor29-32
T-ALL is associated with far fewer genetic alterations than BP-ALL, most of
which involve the juxtaposition of oncogenic transcription factors (HOX11, TAL1,
LYL1, LMO1 and LMO2) to the T-cell receptor (TCR) enhancer and/or promoter
elements20-22, 24, and some gene mutations. Genetic abnormalities involving TCR genes,
basic helix-loop-helix genes (TAL1, TAL2, LYL1, MYC), cysteine-rich LIM domain-
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containing

genes

(LMO1,

LMO2)

or

homeodomain

genes

(HOX11/TLX1,

HOX11L2/TLX3, HOXA gene cluster) can block differentiation, thus resulting in an
more immature phenotype, and promote transformation of normal thymocytes into
malignant blasts25. Genetic mutations in key genes (CDKN2A/2B, CCND2, LCK, RAS,
PTEN, ABL1, JAK2, FLT3) are believed to promote self-renewal of the malignant cells
or leukemic stem-cells, alter responses to extracellular signals that allow for constitutive
activation, which results in enhanced cell survival, and/or block apoptosis9, 33

Recent

studies have shown that improper activation of multiple signal transduction pathways are
involved in the initiation and progression of T-ALL34. Some of the signaling pathways
known to be involved are:
•

NOTCH1

•

Phosphatidylinositol 3-kinase(PI3K)-Akt and mammalian target of rapamycin
(mTOR)

•

Janus kinase (JAK)-signal transducer and activator of transcription (STAT)

•

Nuclear factor-κB (NFκB)

•

Calcineurin/nuclear factor of activated T-cells (NFAT)34.

For example, studies have shown that T-ALLs with elevated levels of NFκB family
members35,including RelB, can promote T-cell leukemogenesis and accelerate leukemia
onset and increased disease severity36.

In another example, murine studies have

demonstrated how activated calcineurin can enhance the aggressiveness of T-ALL cells
and promote leukemia progression37. Although we do not know the exact mechanism
that causes leukemic transformation, we do know that it involves a multistep process in
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which numerous genetic alterations shift the normal thymocyte into uncontrolled growth
and clonal expansion38.
1.3 Treatment and Risk Stratification of ALL
The treatment of pediatric leukemia is an incredible success story.

The

treatment for ALL changed drastically when Sydney Farber, in the late 1940’s,
discovered folic acid given to ALL patients appeared to stimulate the proliferation of
ALL39. Soon after this breakthrough, Farber and collaborators began synthesizing the
antifolates aminopterin and amethopterin (methotrexate) and administered them to
children with ALL40. These antifolates were successfully able to induce remission of the
disease39. This soon lead to the discovery of other antileukemic agents in the 1950’s,
including 6-mercaptopurine41, 42. Even with these discoveries, only 5-10% of leukemia
patients survived in the early 1960’s43. It wasn’t until 1965 that combinational therapy
was introduced. James Holland and colleagues found that a combination of methotrexate,
vincristine, 6-mercaptopurine and prednisone could induce long-term remission in
pediatric ALL44. Today, nearly 80% of all pediatric leukemia patients are cured19-21
(Figure 1).
The continued success of treating and curing leukemia is not the result of new and
innovative drugs. Rather, it’s due to better and more efficient use of existing drugs,
including methotrexate, vincristine, 6-mercaptopurine and corticosteroids43, 45. Today’s
therapy, often referred to as Risk-Adaptive Therapy, is tailored to the predicted risk for
relapse in each patient19. The intensity of treatment is based on the likelihood that
patients will relapse, as leukemic relapse is the most common cause of treatment
failure46. Patients are grouped into risk categories based on key presenting factors, which
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Figure 1: Event-free Survival and Overall Survival of Children with Newly
Diagnosed Acute Lymphoblastic Leukemia

These patients were apart of 15 consecutive studies at St. Jude Children’s Research Hospital from 1962 to
2005. The probability of event-free and overall survival were calculated using Kaplan-Meier analysis.
This figure was taken from Pui, C.H. and Evan, W.E. (NEJM; 2006)20.
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include sex, age, presenting white blood count (WBC), central nervous system (CNS)
involvement status, testicular involvement, leukemia characteristics (lineage, subtype)
and initial therapeutic response19-21,

47, 48

. Initial response to glucocorticoid/prednisone

treatment has been identified as a strong prognostic factor in childhood ALL49-51.
Resistance to glucocorticoids in vitro is associated with an unfavorable prognosis52, 53, as
the majority of patients with relapsed ALL have increased resistance to glucocorticoid
therapy53, 54. Another prognostic marker is the monitoring of minimal residual disease
(MRD) at various times after initial induction therapy55. MRD tracks the clearance of
leukemic cells by RT-PCR and/or flow cytometry techniques2, 56. Patients with MRD
levels >10-3 (i.e., at least 1 leukemic cell is detected out of every 1000 cells) are
considered to be at a high risk of relapse, while patients with MRD levels <10-4 (i.e., at
most, 1 leukemic cell is detected out of every 10,000 cells) are assumed to be at a low
risk of relapse56. Those patients that fall between the high and low levels are considered
to be at a standard risk for relapse. Despite knowing prognostic predictors, treatment
outcome still depends on therapy and the underlying biology of the patient and their
disease45.
ALL is a heterogeneous disease and is comprised of malignant blasts arrested at
different stages of differentiation, associated with expressing characteristic markers19-21.
As a result, risk standards for therapy are also based on immunophenotype and the
absence and/or presence of genetic alterations18-21. There are many genetic alterations in
BP-ALL that confer either a favorable or unfavorable prognosis. For example, t(12;21)
in BP-ALL results in a TEL-RUNX fusion gene and protein and predicts a favorable
outcome. T-ALL is associated with fewer unique features than BP-ALL upon which to
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base therapy20,

21, 24

. This is partly due to the fact that this is a relatively rare disease

(only about 0.54 cases per 100,000 children per year6) and overall there are too few cases
in which the usefulness of these biomarkers can be effectively tested. What is known is
that these patients are prone to early initial relapse and inferior outcome, and as a result,
their long term survival rates lag behind BP-ALL patients nearly 15-20%20, 21, 24. Some
T-ALL subtypes have been associated with treatment outcomes. As mentioned earlier,
these subtypes generally involve a translocation between the T-cell receptor (TCR)
promoter and/or enhancer region and oncogenic transcription factors such as HOX11,
TAL1, LYL1, LMO1 and LMO219-21, 24. For example, translocations involving TAL1
and LYL1 are associated with a poor outcome, while HOX11 translocations are
associated with a much more favorable outcome22. Some genetic mutations have been
shown to be associated with treatment outcomes. For examples, activating mutations in
TAL1 (~50% of T-ALLs) and mutations in LYL1 are associated with inferior outcomes
and survivals22,

57

, whereas mutations in MLL (4-8% of T-ALLs) appear to have no

impact on prognosis57. Mutations in NOTCH1 occur in over 50% of T-ALLs, and its
impact on prognosis and survival has yet to be determined. This is an important focus of
our study.
Patients thought to be at higher risk of relapse are treated with more intensive
therapeutic regimens, and are considered candidates for allogeneic hematopoietic stemcell transplantation2. Typically, older patients, more often male than female, and patients
with presenting WBC > 50,000/µL are at a higher risk of relapse, and thus are treated
more aggressively. Low risk patients are typically treated with antimetabolite therapies
and standard risk patients are treated with intensive multiagent chemotherapies2.
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Contemporary treatment of ALL typically lasts 2 to 2.5 years, and can be divided into 3
periods, remission induction therapy, intensification (consolidation) therapy and
continuation (maintenance) therapy20. The goal of remission induction therapy is to
eliminate at least 99% of the leukemic cells and restore normal hematopoiesis20. During
this period, patients are given glucocorticoid, vincristine and either asparaginase, an
anthracycline, or both. Such treatment has been able to induce complete remission for
nearly 98% of children and 85% of adult ALL patients20. With consolidation therapy,
patients are given high doses of methotrexate with 6-mercaptopurine and high doses of
asparaginase. Often, induction therapy is repeated20. Maintenance therapy lasts for 2 or
more years, and this amount of time has been proven critical for curing the disease20.
This therapy utilizes a combination of daily 6-mercaptopurine and weekly methotrexate
at low doses. Intrathecal chemotherapy has replaced the need of cranial irradiation to
prevent/eliminate CNS leukemia in standard risk patients. Radiation is only used for very
high risk patients, along with allogeneic hematopoietic stem-cell transplantation20. While
many of the same agents and principles are used throughout the world, chemotherapeutic
regimens can vary substantially. Even here in the United States, treatment protocols can
vary among cancer treatment centers. This is most evident by the treatment of ALL in
adolescents and young adults. Depending on the treating facility, this subset of patients
can be treated on either pediatric or adult protocols. Current studies are focusing on the
development of molecular therapeutic agents that can target specific genetic alteration
products, similar to that of imatinib targeting the BCR-ABL fusion product9.
It is not uncommon for patients to develop resistance to chemotherapy and
molecularly-targeted drugs58-60.

Resistance may be due to (i) poor drug uptake or
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enhanced drug metabolism that both result in lower, ineffective intracellular
concentration of the chemotherapeutic drug31. Leukemic cells (ii) may acquire new
genetic abnormalities that can inhibit the drug from interacting with its specific molecular
target, or (iii) they just stop responding to therapy by adapting to the persistent
biochemical activity of the molecules and their targeted pathways31. Another concern is
treatment side effects.

Side effects of chemotherapy (e.g., secondary leukemias,

cardiomyopathy, neuropsychological impairment, infertility) may have a major impact on
the quality of life of patients, years after therapy completion.
1.4 The Biology of NOTCH1
The NOTCH receptor was first discovered in Drosophila (dNotch) where it
caused notches at the end of the wing blade61, resulting in the partial loss of function of
the wing62, 63. While there is only a single NOTCH protein and two ligands (Delta (D1)
and Serrate (Ser)) in Drosophila, mammals, including humans, have 4 NOTCH proteins
(NOTCH1, NOTCH2, NOTCH3 and NOTCH4) and 5 ligands62. NOTCH signaling is
vital to the development of multicellular organisms, as it controls cell fate by regulating
cell proliferation, survival and differentiation64. NOTCH signaling is also important in
adult organisms, where it regulates stem-cell maintenance, binary cell-fate decisions (Tversus B-lymphocyte lineage), and differentiation in self-renewing organs65. All four
human homologues of the NOTCH receptor share the same overall structure, but have
slight differences in extracellular and cytoplasmic domains62. Some NOTCH receptors
appear to have redundant functions in certain contexts (i.e. NOTCH1 and NOTCH4 in
vasculogenesis), while others appear to have unique and essential functions66.

For

example, loss of either NOTCH1 or NOTCH2 is embryonic lethal in mice67. There are 5
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human NOTCH ligands: Delta-like-1, -3, -4 (DLL1, DLL3, DLL4) and Ser-like ligands
Jagged 1 and Jagged 2 (JAG1 and JAG2)68-72.

Much like the receptor, these are

transmembrane proteins that are expressed on the surface of signaling cells73.
The thymus is the site of T-cell development. Progenitor cells, which are derived
in bone marrow, are released into the bloodstream and travel to the thymus. Interactions
with thymic stromal cells induce signals within progenitors that direct T-cell
commitment, migration, proliferation and differentiation74,

75

. NOTCH1 signaling is

absolutely necessary for T-cell development. In the thymus, progenitor cells bind to
NOTCH1 ligands that are embedded in the membrane of thymic stromal cells74,

75

,

triggering NOTCH1 signaling and subsequent T-cell commitment. Different NOTCH1
signaling thresholds stimulate different cellular processes. Low signaling is responsible
for the inhibition of B-cell development, while high signaling promotes progenitor
proliferation and progression into the double positive stage75. Mouse models have shown
that NOTCH1 inactivation results in the generation of B-cells and the inhibition of T-cell
development76, 77. Similar studies have shown constitutive NOTCH1 signaling promotes
the inhibition of B-cell development24.
1.5 Overview of NOTCH1 Signaling
NOTCH1 is a 2550 amino acid single pass transmembrane receptor with a
molecular weight of 350kDa38,

78, 79

.

NOTCH1 is comprised of 3 subunits: an

extracellular (EC) subunit, a transmembrane (TM) subunit and an intracellular (ICN)
subunit (Figure 2). The EC is comprised of 36 epidermal growth factor (EGF)-like
repeats that bind to membrane-embedded ligands of the Delta-Serrate-Lag2 (DSL) family
on neighboring cells80-82. There are three iterated Notch/Lin12 repeats that maintain the
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Figure 2: The Structures of NOTCH1 and FBW7
A: NOTCH1
Extracellular

Intracellular (ICN)

EGF-like Repeats

Ankyrin

PEST

H
Lin/Notch repeats

TM
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TAD

B: FBW7
NLS

α
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γ
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F-box
WD40 Repeats
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(A) The heterodimeric NOTCH1 receptor consists of extracellular, transmembrane and intracellular
subunits. (B) The E3-ubiquitin ligase FBW7 has 3 isoforms, a, b, and g. Abbreviations: EGF, epidermal
growth factor; HD, heterodimerization; TM, transmembrane; RAM, RBP-jκ-associated molecule; TAD,
transactivation domain; NLS, nuclear localization sequence; DD, dimerization domain.
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receptor in the “off” state in the absence of ligand. At the C-terminus of the EC subunit,
there is a 103 amino acid span that is responsible for the dimerization of the EC to a 65
amino acid region in the TM region of ICN. This dimerization is mediated via the
heterodimerization (HD) domain. ICN mediates NOTCH1 signaling. It contains a RAM
domain that binds to the transcription factor CSL (CBF-1/Su(H)/Lag-1), seven iterated
ankyrin (ANK) repeats, and a C-terminal PEST sequence that regulates protein
turnover80-82.
The receptor is initially translated into a single protein in the Endoplasmic
Reticulum83,

84

.

Upon transport to the Golgi, it undergoes several posttranslational

modifications, including cleavage by a furin-like protease and glycosylation by fringe
proteins83,

84

. The glycosylation status of the receptor determines ligand specificity74.

The two receptor halves dimerize at the HD domain prior to insertion into the cell
membrane. Following ligand binding, the receptor undergoes two additional cleavages in
the TM region85-87. The first cleavage is carried out by an Adam protease at the cell
surface, which removes the EC. The second cleavage is carried out by γ-secretase, and
results in the release of ICN. The free ICN translocates to the nucleus, where it binds to
CSL, converting it to a co-activator78, 79, 85. ICN also recruits additional co-activators,
such as Mastermind-Like (MAML) and histone acetyltranferases78,

79, 85

(Figure 3).

NOTCH1 signaling is regulated by the ubiquitin/proteasome degradation pathway88.
Itch, an E3 ubiquitin ligase, can ubiquitinate membrane-associated NOTCH189. Itch can
also cooperate with NUMB, another E3 ubiquitin ligase, to enhance the ubiquitination of
NOTCH1, and ultimately prevent the nuclear localization of ICN, thus inhibiting
NOTCH1 signaling90.
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The activated form of NOTCH1, ICN, is regulated by the tumor suppressor F-box
and WD repeat domain-containing 7 (FBW7; also known as hCDC4, FBXW7, and
hAGO)91-93. FBW7 is an E3 ubiquitin ligase and a component of SCF (SKP1, CUL1, Fbox) type ubiquitin ligases94. It can target ICN for proteasomal degradation by binding to
a conserved phosphodegron motif (CPD) in the PEST domain that is anchored by
T251592-94. This CPD motif in ICN is hyperphosphorylated by cyclin-dependent kinase
891-93, 95.
FBW7 is located on chromosome 4 and has three alternative transcripts (α, β, γ)
that are the result of alternative splicing96. All three isoforms share the same functional
domains (Figure 2). FBW7 is comprised of multiple protein-protein interacting domains.
The f-box domain recruits SCF via binding to SKP197. The eight WD40 repeats bind to
the substrate at the CPD motif94,

98, 99

. WD40 repeats 3 and 4 contain three highly

conserved arginines that mediate substrate binding98, 99. The D domain, which lies in
front for the f-box, regulates dimerization98, 100-102.
Few NOTCH1 transcriptional target genes have been identified. They include
regulators of apoptosis and cell cycle, including cMYC103-105, Hairy and Enhancer of
Split (HES1), HES-Related Protein (HERP) and Deltex1 (DTX1). HES1, HERP and
DTX1 are all basic helix-loop-helix (bHLH) family members106-108 that act as NOTCH1
effectors by negatively regulating the expression of downstream target genes106,

109-111

.

HES1 and HERP bind to the promoter of its target genes as a dimer with themselves or
other family members106. HES1 has several target genes, including itself, the proneural
gene Mash1, CD4, and the cyclin-dependent kinase inhibitor p21WAF

109, 112-114

. The

downstream effects of DTX1 are controversial, as this E3 ubiquitin ligase115 has been
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Figure 3: An Overview of NOTCH1 Processing and Signaling Activities

This figure was taken from Pui, C.H. et al. (Lancet; 2008)9.
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shown to be both a positive

116, 117

and negative regulator118-120 of NOTCH1 signaling

activity.
cMYC was first identified as a direct downstream target of NOTCH1 in a study
by Weng et al.105. Expression profiling with the T6E murine T-ALL cells identified
cMYC as a direct transcriptional target of NOTCH1 signaling. Palomero et al.104 used
expression profiling with 7 T-ALL human cell lines with constitutively active NOTCH1
that had been treated with a small molecule inhibitor of γ-secretase (GSI), called
compound E, to identify 38 upregulated genes and 201 downregulated genes that
included biosynthetic pathway genes. By integrating gene expression array results and
ChIP-on-ChIP analysis of promoter sequences, cMYC was further identified as a major
target of NOTCH1 signaling. It does appear that the downstream effects of NOTCH1
signaling are context-dependent and vary in different cell types and under different
conditions38,

78, 79

. Thus, depending on the cell type, NOTCH1 signaling can exert

positive or negative effects on proliferation, differentiation and apoptosis.
1.6 Discovery of NOTCH1 in T-ALL
The role of NOTCH1 in T-ALL was first suggested when a translocation between
the receptor and TCRβ was discovered. In t(7;9)(q34;134.3), the promoter region of
TCRβ is fused to the intracellular subunit of NOTCH1121 and results in constitutively
active NOTCH1 signaling that alters its downstream effects on gene transcription. In
mice, constitutively active NOTCH1 has been shown to inhibit B-cell development and
significantly induce T-ALL122-124. However, t(7;9) occurs in less than 1% of T-ALL
cases. In 2004, the significance of NOTCH1 in T-ALL grew considerably. Weng et
al.125 tested human T-ALL cell lines lacking the t(7;9) for NOTCH1 dependency by
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inhibiting NOTCH1 signaling with a GSI. GSIs inhibit γ-secretase from cleaving ICN,
thus preventing its translocation to the nucleus. Of the 30 T-ALL cell lines examined,
only 5 (ALL-SIL, DND-41, HPB-ALL, KOPT-K1, TALL-1) showed G0/G1 cell cycle
arrest, suggesting that these cells were dependent upon NOTCH1 signaling for
survival125. Sequencing of the NOTCH1 receptor across the HD and PEST domains
revealed that NOTCH1 was mutated in 4 of the 5 GSI-sensitive T-ALL cell lines, as well
as in 9 of the 10 GSI-resistant T-ALL cell lines. The clinical relevance of NOTCH1
mutations was confirmed when they screened 96 pediatric diagnostic T-ALL specimens
for NOTCH1 mutations in both the HD and PEST domains and found that 54 (56.2%)
patients harbored such mutations. There did not appear to be any association between the
presence of mutations and T-ALL subtypes, which has been confirmed by subsequent
studies. Since these mutations are not present in the remission bone marrow samples of
NOTCH1 mutant patients, it appears that these mutations are acquired within the
malignant clones125. These mutations, ranging from simple point mutations to large
insertions and deletions that drastically alter the amino acid sequence and can result in
early termination, are found mainly in the HD and PEST domains87, 107, 125-127, but can
also be located in the juxtamembrane (JME) region128. Mutations in the HD domain
affect dimer stability, thus making the receptor more sensitive to γ-secretase127, 129, even
in the absence of ligand. Mutations in the PEST domain increased the receptor’s halflife127, and can prevent its recognition by FBW7 and subsequent proteasomal
degradation. Reporter gene assays have demonstrated that these mutations can render the
receptor constitutively active125. However, to date, the activating effects of NOTCH1
mutations have only been confirmed in a few cases. It appears that not all mutations
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effect NOTCH1 signaling in the same manner, as mutational effect have been reported as
ranging from non-functional to significantly activating127, 129.
Recent reports have also described a high frequency of mutations in the FBW7
substrate binding domain (WD40 repeats) in up to 30% of pediatric T-ALLs91-93 that
would alter NOTCH1 signaling. Such mutations prevent the binding of FBW7 to ICN
and subsequent ubiquitination, thus leading to prolonged activity of ICN. Likewise, it’s
believed that mutations in the PEST domain of ICN lying within the CPD will prevent
recognition and binding of FBW7 and also result in prolonged NOTCH1 signaling
activity. Some of these studies have found patients with mutations in FBW7 and/or
NOTCH1 have a more favorable outcome91.
1.7 The Clinical Significance of NOTCH1
The mechanism in which abnormal NOTCH1 signaling is involved in the
deregulation of thymocyte development and subsequent T-ALL leukemogenesis is not
well understood. It’s widely believed that the oncogenic effect of constitutively active
ICN in T-cells is associated with its capability to promote T-cell commitment and
thereafter block differentiation at the double positive (CD4+CD8+) stage. It is likely that
aberrant NOTCH1 signaling cooperates with other signaling pathways to promote cell
survival in hematopoietic stem cells (HSCs) and T-cell precursors38,

130

.

This

uncontrolled proliferation is thought to put these cells at a higher risk of acquiring more
genetic abnormalities that further promote transformation38, 130.
1.7a The Clinical Significance of NOTCH1 in Pediatric T-ALL
Since the landmark study by Weng et al.125 that first describe the presence of
NOTCH1 mutations in pediatric T-ALL patients, several groups have tried to determine
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Table 1: Summary of Pediatric and Adult T-ALL Studies Assessing the Prognostic
Value of NOTCH1 Mutations Alone or in Combination with FBW7 Mutations.
AUTHORS

YEAR

SPECIMEN

MUTATION
FREQUENCY

PROTOCOL

Zhu, Y. et al.

2006

53 Pediatric T-ALL
24 Adult T-ALL

NOTCH1 (37.7%)

Ped: VDLP;
hd MTX
Adult: VDCP;
hd MTX

Breit, S. et al.

2006

157 Pediatric TALL

NOTCH1 (52.2%)

ALL-BFM 2000

Mansour, M.R.
et al.

2006

24 Adult T-ALL

NOTCH1 (70.8%)

UKALLXII

Malyukova, A.
et al.

2007

26 Pediatric T-ALL

NOTCH1 (30.8%)
FBW7 (30.8%)
Both (7.7%)

NOPHO

Van Grotel, M.
et al.

2007

72 Pediatric T-ALL

NOTCH1 (55.6%)

DCOG ALL-7,
ALL-8 or
ALL-9

Mansour, M.R.
et al.

2009

88 Adult T-ALL

NOTCH1 (60%)
FBW7 (18%)
Both (21%)

UKALLXII/
ECOG2993

Marks, D.I. et al.

2009

356 Adult T-ALL

NOTCH1 (61%)
FBW7 (18%)
Both (3%)

UKALLXII/
ECOG2993

Asnafi, V. et al.

2009

141 Adult T-ALL

NOTCH1 (62%)
FBW7 (24%)

LALA-94
GRAALL-2003

Baldus, C.D.
et al.

2009

126 Adult T-ALL

NOTCH1 (57%)
FBW7 (12%)

GMALL 05/93
or 06/99

FINDINGS
NOTCH1 mutations were more
frequent in patients with WBC count
>10x109/L; Poor relapse-free survival
and overall survival rate were
correlated with NOTCH1 mutation;
NOTCH1 mutations were significantly
associated with poorer prognosis in
Adult T-ALL patients.
NOTCH1 mutant patients had an
event-free survival of 90% compared
with 71% in wild-type patients
NOTCH1 mutations may be good
MRD markers.
NOTCH1 mutations alone or in
combination with FBW7 mutations
show a strong association with
favorable outcome.
EGIL or TCR classification subgroups
are not associated with outcome.
Presence of NOTCH1 mutations is not
associated with disease-free survival.
There is a trend towards better EFS in
patients with at least 1 mutations in the
Notch pathway; this is not significant
Patients with mutations in NOTCH1
and/or FBW7 have higher event-free
survival than wild-type patients (51%
vs. 27%), but this is not significant
NOTCH1/FBW7 status is a major
prognostic significance and confer
overall good results for T-ALL
No significant differences were
observed in the complete remission,
relapse, or event-free survival rates
between NOTCH1/FBW7 wild-type
and mutant cases.
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the prognostic value of these mutations in both pediatric and adult T-ALLs, and whether
or not they could be used to stratify patients for therapy. These studies are summarized
in Table 1. In 2006, Zhu et al.131 published a report examining the prognostic value of
NOTCH1 mutations in 24 adult and 53 pediatric T-ALL patients, who were treated with
very similar protocols. In total, 29 of 77 patients had NOTCH1 mutations. These
mutations were located in the HD, PEST, TAD and ANK domains.

They found

NOTCH1 mutations were more common in patients with presenting WBC over 10x109/L.
NOTCH1 mutations were also correlated with poor relapse-free survival and overall
survival rates, such that the 3 year relapse free survival and overall survival rates for
patients with NOTCH1 mutations were 28.8% and 31.8% respectively, significantly
shorter than patients without mutations (59.8% and 71.7%; p=0.0053). However, when
the patient cohort was divided by age groups, they found that in the pediatric T-ALL
patients (<18 years old), there was no significant difference in survival between those
patient who harbored NOTCH1 mutations and those who did not. In contrast, the adult
T-ALL patients with NOTCH1 mutations had a far worse overall survival rate than those
who were wild-type for NOTCH1 (p=0.0041). At least in this adult cohort, NOTCH1
mutations were associated with a poor prognosis131.
That same year, Breit et al.132 published a report that suggested NOTCH1
mutations were associated with a more favorable outcome132.

In this study of 157

pediatric T-ALLs treated with a single protocol (ALL-BFM 2000), 52.2% of the cohort
harbored NOTCH1 mutations. Nearly 62% of these mutations were novel (i.e., were
different from those reported by Weng et al.125). For this cohort, treatment response was
assessed by MRD measurements at 33 and 78 days after the completion of induction
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therapy. At both time points, most of the T-ALL patients with a favorable MRD status
(<10-4) also harbored NOTCH1 mutations. Not surprisingly then, NOTCH1 mutations
were more prevalent in prednisone good-responders than in the poor-responder group
(p=0.001); therefore patients with NOTCH1 mutations were 3 times less likely to show a
poor prednisone response. Patients with NOTCH1 mutations also showed a significantly
better relapse-free survival compared with those without mutations (p=0.004). In this
pediatric cohort, NOTCH1 mutations had favorable effects on treatment response, with a
better relapse-free survival132.
The pediatric T-ALL patients in the Zhu131 and Breit132 studies were treated with
different treatment protocols. Both protocols used similar chemotherapeutic drugs, but
the dosing schedule and amounts varied. In both protocols, induction therapy included
the use of vincristine, daunorubicin (or similar analog) and L-asparaginase, followed by
treatment with cyclophosphamide, cytarabine and 6-mercaptopurine.

The main

differences between the 2 protocols was that in the ALL-BFM 2000 protocol used by
Breit et al. report, induction therapy included a 7-day monotherapy with orally
administered prednisone and 1 dose of intrathecal methotrexate, and MRD analysis at
days 33 and 78 were used for risk-adapted treatment stratification133. This suggests that
the prognostic value of NOTCH1 mutations may be treatment-dependent. Further studies
are needed to confirm this. It should also be noted, as mentioned previously, adult TALL patients typically have many poor prognostic markers associated with their disease.
Accordingly, the presence of NOTCH1 mutations may have very little effect on outcome
in these patients.

23
In a 2007 report, Malyukova et al.91 confirmed the major findings of Breit et
al.132. In this study, they analyzed a small cohort of 26 pediatric T-ALLs, who were
treated with high-risk protocols prepared by the Nordic Society of Pediatric Hematology
and Oncology (NOPHO).

This treatment protocol included pulses of high-dose

methotrexate alone, or in combination with high-dose cytosine arabinoside, in
conjunction with multiple intrathecal injections of methotrexate134. Of the 26 patients
analyzed, 8 patients (30.8%) harbored NOTCH1 mutations and 8 patients had mutations
in the E3 ubiquitin ligase FBW7, which has been reported to result in elevated levels of
ICN. Only 2 of the 26 T-ALL patients had mutations in both NOTCH1 and FBW7.
They found that NOTCH1 mutations alone, or in combination with FBW7 mutations,
were associated with favorable outcome91.
Adding to the controversy in 2008 was a report published by van Grotel et al.135
in which they found no associations between NOTCH1 mutations and treatment outcome
in a sizable cohort of 72 pediatric T-ALL patients135, all of whom were treated according
to Dutch Childhood Oncology Group (DCOG) protocols. These protocols are described
as being very similar to the ALL-BFM90 protocols, using high doses of intravenous 6mercaptopurine with medium risk patients, high doses of L-asparaginase in standard risk
patients, and avoidance of cranial irradiation. In this pediatric cohort, 40 of the 72 TALL patients (55.6%) had at least 1 mutation in NOTCH1. There was absolutely no
association between the presence of NOTCH1 mutations and disease-free survival.
Collectively, the results of these studies of pediatric T-ALLs suggest that the
presence of NOTCH1 mutations may not be a reliable prognostic indicator and that its
ability to predict prognosis may rely on other factors, including initial response to
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therapy, which in and of itself is highly dependent upon the biology of the disease.
However, caution must be taken when comparing these reports head-to-head, as the
pediatric cohorts were treated with different therapeutic regimens and not all patients
shared that same risk for relapse. It is very likely that the chemotherapeutic protocol can
influence the prognostic value of NOTCH1 mutations. Future studies are warranted in
which NOTCH1 mutations are analyzed in patient cohorts treated with very similar
chemotherapeutic protocols. What we do know is that NOTCH1 mutations play both an
initiating role in the leukemogenic process, as mutations have been identified in a T-ALL
patient at both diagnosis and 7 years before the development of full blown leukemia136,
and a secondary role in disease progression, as mutations have also been identified in
subclonal populations137 that can eventually lead to relapse.
1.7b The Clinical Significance of NOTCH1 in Adult T-ALL
Similar studies focusing on the prognostic value of NOTCH1 mutations were
conducted with adult T-ALL cohorts. As noted above, adult T-ALL is considered to be
more aggressive and has much more dismal overall survival rate than pediatric T-ALL.
In 2006, Mansour et al.138 in a cohort of 24 adult T-ALL patients treated on the MRC
UKALLXII trial, identified 17 patients (70.8%) who harbored NOTCH1 mutations. As
had been reported in the pediatric T-ALL, the NOTCH1 mutations were not detected in
remission. Thus, NOTCH1 mutations may be good markers for MRD detection. In
another study, Mansour et al.139 analyzed the presence of NOTCH1 mutations in 88 adult
T-ALL patients. While 53 patients (60%) had NOTCH1 mutations, they were evenly
distributed between the standard- and high-risk groups. There was a trend towards better
event-free survival (EFS) and overall survival (OS) rates in patients with NOTCH1
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mutations compared those who were wild-type (51% vs. 27% (EFS) and 54% vs. 41%
(OS)), but this trend was not significant (p=0.1 and p=0.3).
In a study by Asnafi et al.140, of the 141 adult (>15 yrs old) T-ALL patients
treated with either the Lymphoblastic Acute Leukemia in Adults (LALA)-94 (87
patients) protocol or the pediatric-inspired Group for Research on Adult Acute
Lymphoblastic Leukemia (GRAALL)-2003 (54 patients) protocol, NOTCH1 mutations
were identified in 88 (62%) cases and FBW7 mutations were present in 34 cases (24%).
Overall, 101 cases were classified as NOTCH1 and/or FBW7 mutant (70%). There was a
trend for a higher WBC count and more frequent CNS involvement in patients with wildtype NOTCH1. This is likely due to the fact that high risk features, such as age over 35
and WBC >100 g/L, were found much more frequently in the NOTCH1/FBW7 wild-type
patients (72.5% vs. 55%; p=0.085). The complete remission rate was similar in patients
with NOTCH1 mutations as compared to WT NOTCH1 patients. However, the median
EFS was significantly less in the wild-type patients (22 months vs. 36 months; p=0.03).
Interestingly, the median overall survival was 38 months for wild-type patients, but had
not yet been reached for the mutant NOTCH1/FBW7 patients (p=0.03) at the time this
report was published. This study suggests that NOTCH1/FBW7 status has significant
prognostic value in modern trials and gives overall good results for adult T-ALL.
In another report, Baldus et al.141 analyzed the prognostic value of NOTCH1 and
FBW7 mutations in 126 adult T-ALL patients on the GMALL 05/93 and 06/99 protocols.
Both of these protocols included intensive chemotherapy and autologous or allogeneic
stem cell transplantation.

NOTCH1 mutations were identified in 72 of the 126 (57%)

patients, and FBW7 mutations were found in 14 of the 112 patients (12%). It was
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observed that the wild-type NOTCH1/FBW7 patients predominantly exhibited an
immature double-negative phenotype that was defined by a lack of CD1a, CD4, CD8 and
CD3 expression.

CD1a expression was highly indicative of presence of NOTCH1

mutations, suggesting that this may be a direct target of NOTCH1 signaling (p<0.001).
There was no significant difference observed in the complete remission, relapse or EFS
rates between wild-type NOTCH/FBW7 and mutant NOTCH1/FBW7 patients,
suggesting that there is no prognostic value for NOTCH1/FBW7 mutations.
In a large study by Marks et al.142, the presence of NOTCH1 and FBW7
mutations was analyzed in 356 adult T-ALL specimens. These patients were treated on
the UKALLXII/ECOG2993 protocol, the same as the Mansour et al.139 study. NOTCH1
mutations were present in 61% of the cohort and FBW7 mutations were seen in 18% of
the patients. Only 3% of the cohort had mutations in both NOTCH1 and FBW7. It was
observed that patients with NOTCH1/FBW7 mutations had a higher EFS when compared
to wild-type patients (51% vs. 27%), however this was not significant. Nearly 37% of the
cohort experienced a relapse that occurred at a median of 12 months, with the majority
arising within 2 years of remission. The overall 5-year survival rate for this cohort was
48%. It was observed that the overall survival in CD1a+ patients was 64%, compared
30% in CD1a- patients. This suggests that CD1a status may be a prognostic indicator.
Much like the pediatric studies, the adult T-ALL studies do not give any definitive
evidence to the prognostic value of NOTCH1 mutations. Again, this could possibly be
due to the fact that in these studies, patients were treated with different chemotherapeutic
protocols. With reports from Marks et al.142 and Mansour et al.139 , where the patients
were treated with the identical protocol, they could only conclude that there was a trend
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towards better survival in patients with NOTCH1/FBW7 mutations. Thus, the prognostic
value of NOTCH1 mutations in both pediatric and adult T-ALLs remains extraordinarily
controversial.
1.7c The Clinical Significance of NOTCH1 in Solid Tumors
Aberrant NOTCH signaling has been implicated to play a role in the biology of
solid tumors as well. However, unlike T-ALLs, abnormal NOTCH signaling is not
caused by mutations to the receptor. Instead, it’s due to increases in expression for both
NOTCH1 ligands and receptors. For example, an upregulation of Jagged1 mRNA has
been observed in pancreatic cancer143 and the over expression of Jagged1 protein has
been reported in cancers of the prostate144, cervix145 and brain146, 147. The upregulation of
Jagged2 mRNA has also been observed in cervical cancer145, along with Jagged2 protein
over expression reported in pancreatic cancer143. DLL1 mRNA has been reported as
being over-expressed in both cervical145 and brain cancers, where proteins levels are
elevated as well147. There is an increase in expression of NOTCH1, at the protein level,
in cancers of the cervix145, 148, colon148, lung148, pancreas143, skin149 and brain146, 147. The
role of NOTCH1 signaling has been most extensively studied in breast cancers. In a
clinical study of 7 breast cancer specimens, NOTCH1 protein expression was detected to
a greater extent in all the tumors examined but not in the normal breast tissue at the
margins of the tumors150. In another study of 25 breast cancer specimens, the mRNA
expression of all 4 NOTCH receptors were detected at varying frequencies151. In a
subsequent study involving 97 specimens, elevated NOTCH1 protein levels were
associated with reduced patient survival152. It’s estimated that more than half of all
human breast tumors express reduced protein levels of Numb, a negative regulator of
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NOTCH signaling and that a negative correlation exists between Numb expression and
breast tumor grade153.
1.8: Therapeutic Targeting of NOTCH1
NOTCH1 is believed to be an ideal target for therapy because it’s mutated form is
generally considered to increase the overall activity of the receptor in >50% of T-ALLs
and it can easily be inhibited by small molecule inhibitors, called γ-secretase inhibitors
(GSIs), which prevent the cleavage of the intracellular form, an essential requirement for
activity. GSIs have been shown to induce cell-cycle arrest at G0/G1, decrease cell
viability and cause some apoptosis in a subset of T-cell lines carrying NOTCH1
activating mutations125,

154

. The problem with GSIs is that they are not specific to

NOTCH1, as γ-secretase targets over 30 other transmembrane proteins, one of which is
the amyloid precursor protein involved in Alzheimer’s disease155. Animal studies had
shown that systemic inhibition of NOTCH signaling results in gastrointestinal toxicity
because of the accumulation of secretory goblet cells in the intestine156-159. Initial clinical
trials using GSIs have failed miserably160, 161. A Phase 1 clinical trial conducted by the
Dana-Farber Cancer Institute (04-390) used the GSI MK-0725 for 7 patients with
relapsed T-ALL.

This trial revealed that GSIs caused severe, dose-limiting,

gastrointestinal toxicities160, 162. Similar gastrointestinal toxicities have been seen in the
GSI clinical trials for Alzheimer’s disease, along with skin and immune system
abnormalities157, 159, 163. The T-ALL clinical trials also suggested that GSIs may be more
cytostatic than cytotoxic in humans as they were unable to induce significant apoptosis in
T-ALL leukemic blasts in patients125,

164

. Despite these clinical findings, inhibition of

NOTCH1 signaling has been reported to exert a profound effect on the regulation of T-
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ALL lymphoblasts104,

165, 166

, suggesting that GSIs may sensitize T-ALL cells to

chemotherapy167. One characteristic that makes GSIs potentially attractive therapeutic
agents is that they can penetrate the blood-brain barrier, as is evident from the
Alzheimer’s disease studies167,

168

. Accordingly, if such molecules can be safely and

effectively used in combinational chemotherapy, they may aid in the elimination of CNSsequestered T-ALL.
To further explore the sensitizing of T-ALL to chemotherapy by GSIs, Real et
al.169 examined the effects of GSIs in combination with glucocorticoids in T-ALL cells.
Using a glucocorticoid resistant T-ALL cell line (CUTLL1) and primary pediatric T-ALL
specimens, they found that GSIs could inhibit NOTCH1 signaling, render the cells more
sensitive to glucocorticoids, and result in glucocorticoid-induced apoptosis. Thus, it
appears that the use of GSIs can reverse glucocorticoid resistance. Interestingly, this
effect was specific to glucocorticoids as GSIs did not sensitize T-ALLs to etoposide,
methotrexate, vincristine and L-asparaginase. This reversal of glucocorticoid resistance
is likely due to the increased expression of the glucocorticoid receptor (NR3C1) and
glucocorticoid-regulated genes upon NOTCH1 inhibition169. Real et al. demonstrated the
NOTCH1 target, HES1, can bind to the glucocorticoid receptor promoter and inhibit its
expression. Thus, upon NOTCH1 inhibition, there is a decrease in the expression of
HES1, thereby releasing the negative transcriptional regulation of the glucocorticoid
receptor. In vivo studies validated the effectiveness of the combination of GSIs and
glucocorticoids. Also surprising was that glucocorticoid treatment seemed to decrease
the gastrointestinal toxicities associated with GSI usage.
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In a study by Cullion et al.170 mice with end-stage T-ALL were treated with the
GSI MRK-003, and it appears that this extended the life of these mice but did not cure the
disease. Cells isolated from GSI-treated mice exhibited increased mTOR activity, which
can promote cell survival (see below for more on mTOR). These results imply that
mTOR inhibitors may synergize with GSIs. In fact, the treatment of mouse T-ALL cells
with both GSI and the mTOR inhibitor rapamycin resulted in an escalation of
apoptosis170. The combined treatment of GSIs and rapamycin decreased the proliferation
of the leukemic cells and increased overall survival of the mice. This study provides
further evidence that NOTCH1 inhibition, possibly through the use of GSIs, is a potential
therapeutic option. Obviously, further studies are needed.
1.9 The PI3K-Akt and mTOR Pathways and Their Involvement in T-ALL
It has been suggested that the constitutive expression of oncogenic responder
genes (such as MYC) and the activation of other signaling pathways (PI3K/Akt/mTOR)
may account for how NOTCH1 drives the pathogenesis of T-ALL25. NOTCH1 signaling
has been implicated to play a direct role in both the PI3K-Akt and mTOR pathways
(Figure 4; discussed in more detail below). These two highly intertwined pathways are
linked to cell survival and proliferation. The pathways are stimulated by the activation of
the phosphatidylinositol-3-kinases (PI3Ks) by receptor tyrosine kinases.

The PI3Ks

function as a heterodimer, consisting of a catalytic subunit and a regulatory subunit.
There are 2 subclasses of PI3Ks, class 1A and class1B. Class 1A PI3Ks consists of the
catalytic subunits PIK3CA (p110α), PIK3CB (p110β) and PIK3CD (p110δ), along the
regulatory subunits PIK3R1 (p85α, p55α, p50α), PIK3R2 (p85β) and PI3KR3 (p55γ)171.
PIK3CA and PIK3CB are expressed ubiquitously, while PIK3CD is expressed mainly in
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leukocytes. PIK3R1 (p85a) and PIK3R2 are also widely expressed in most cell types,
while the other isoforms have a more limited expression171.

PIK3CG

is the only

catalytic member of class IB PI3Ks, and is expressed mainly in leukocytes171. The PI3K
heterodimers

phosphorylate

phosphatidylinositol

4,5-bisphosphate

(PIP2)

to

phosphatidylinositol 3,4,5-triphosphate (PIP3). The accumulation of PIP3 on the cell
membrane recruits both Akt and phosphoinositide-dependent protein kinase 1 (PDK1),
and leads to the phosphorylation of AKT on T308172. Once Akt is phosphorylated at
S473 by mTOR2, it is fully active173. It is the downstream effects of Akt that promote
cell survival and activation (cell growth, increased glucose uptake and oxidation, cell
cycle progression and cell survival through multiple direct and indirect mechanisms174179

). Akt can also phosphorylate tuberous sclerosis 2 (TSC2), disrupting the tuberous

sclerosis 1 (TSC1)-TSC2 complex, thus releasing the inhibition of a Ras homologue
enriched in brain (RHEB),which can, in turn, activate mammalian target of rapamycin
(mTOR1)180. cMYC, a downstream target of NOTCH1 has also been shown to inhibit
TSC2, leading to the activation of mTOR1181. mTOR1 is a complex comprised of the
catalytic mTOR subunit, raptor and mLST8182. mTOR1 can stimulate the synthesis of
proteins needed for cell growth, survival and metabolism by directly phosphorylating and
activating ribosomal S6 kinase 1 (S6K1), and eukaryotic translation initiation factor 4E
binding proteins (4EBP)182, 183. S6K1 has been shown to be involved in a feedback loop
for the PI3K-Akt pathway by inhibiting insulin receptor substrate 1 (IRS1), which in turn
inhibits the initial activation of AKT182. Little is known about the regulation of mTOR2.
It too is a complex comprised of the catalytic mTOR subunit and mLST8, but it also
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Figure 4: The Role of NOTCH1 Signaling in the PI3K-Akt/mTOR Pathways
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Loss of PTEN, either by inhibition of by HES1, mutations, or posttranslational modifications, results in
hyperactivated AKT and mTOR signaling. Rapamycin is an inhibitor of mTOR1, and results in the
inhibition of cell growth and cap-dependent translation. In certain contexts, mTOR2 may also be inhibited.
Repression of TSC2 transcription by cMYC results in increased mTOR1 activity.
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contains rictor and mSin1182. The mTOR2 complex is directly involved in the PI3K-Akt
pathway by its phosphorylation of Akt at S473, leading to its full activation.
The tumor suppressor PTEN (phosphatase and tensin homolog) is a plasmamembrane lipid phosphatase that negatively regulates the activity of the PI3K-Akt
pathway184. It has been described as an indirect target of NOTCH1 (via HES1 and
cMYC), resulting in increased PI3K-Akt signaling166 (Figure 4).

When PTEN is

rendered non-functional, whether by deletion, mutation or posttranslational modifications
(see below), subsequent inactivation of PI3K targets (mainly Akt) can occur in the
absence of stimuli175. Numerous tumor types can be linked to alterations in PTEN
expression185, including homozygous and heterozygous somatic mutations186-188.
Palomero et al. found 17% of T-ALL cases at diagnosis harbored complete loss of the
PTEN protein166, with 8% of the T-ALL specimens harboring PTEN mutations. In a
small number of paired diagnostic and relapse samples, relapse specimens had loss of
PTEN, suggesting that the loss of PTEN is associated with tumor progression in TALL166.
PTEN defects in mouse models recapitulate the broad tumor spectrum often seen
in humans, including T-cell malignancies189, 190. Several human T-ALL cell lines lack
PTEN as a result of deletions or mutations to the gene191,

192

.

As expected, such

alterations result in the constitutive activation of the PI3K-Akt pathway. Studies have
also shown that the activity of PTEN can be down regulated by post-translational
activities such as phosphorylation and oxidation193-196 and also by the activities of
miR19197. In a study by Silva et al., it was found that nearly 88% of patients in a cohort
of 24 T-ALLs had hyperactivation of the PI3K-Akt pathway198. While some specimens
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had alterations in their PTEN coding sequence and some had an overall lack of PTEN
expression, a vast majority of the specimens had wild-type PTEN protein expression in
conjunction with hyperactivation of PI3K-Akt pathway. It was determined that PTEN
activity was downregulated by casein kinase 2 (CK2)-mediated phosphorylation and
ROS-dependent oxidation of PTEN198. This suggests that the potential impact of PTEN
in T-ALL and on chemotherapeutic response in this disease is immense. It has also been
shown that leukemia cells over-express CK2198, and that both wild-type and mutant
NOTCH1 T-ALL specimens have significantly higher PTEN protein levels than normal
human thymocytes. There is experimental evidence that the treatment of T-ALL cell
lines with GSI and CK2-specific inhibitors have a mild but consistent cooperative effect
in diminishing leukemia proliferation198, 199. This suggests that the combination of GSIs
with CK2 inhibitors, or even Akt inhibitors may be beneficial in the treatment of T-ALL.
There are several other potential mechanisms in which the activity of PI3K-Akt pathway
can be inhibited in combination with GSIs. They include pan- and isotype-specific
inhibitors of the PI3Ks, as well as Akt inhibitors, some of which have begun clinical
trials172. One of the major downstream effectors of Akt signaling is mTOR1, which can
be effectively inhibited by rapamycin. As mentioned previously, mouse studies have
shown that GSIs may synergize with rapamycin to induce apoptosis in T-ALL170.
In a more detailed study, Silva et al.199 found that in the 9 patients with NOTCH1
mutations (out of a cohort of 19 pediatric T-ALLS), there were significantly elevated
PTEN mRNA levels (p=0.021) and lower PTEN protein levels. The use of GSIs resulted
in an up-regulation of PTEN protein expression. Palomero et al. demonstrated that
growth arrest induced by GSI treatment of T-ALL cell lines was similar to the growth
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defect caused by nutrient deprivation, cytokine withdrawal and inhibition of the PI3K
pathway166. Both of these studies provide further evidence linking NOTCH1 signaling to
the PI3K-Akt pathway.

The Palomero report166 further demonstrated that both HES1

and cMYC can bind to the PTEN promoter in T-ALL cells. HES1 reduces the activity of
PTEN promoter, while MYC can cause a moderate increase in PTEN promoter activity.
However, it’s believed that the MYC induction of PTEN expression is overridden by the
activity of HES1. The combined effects of HES1 and MYC downstream of NOTCH1
signaling in T-cell progenitors is thought to increase the activity of the PI3K-Akt
signaling pathway in response to extracellular stimuli and to promote cell growth without
inducing full oncogenic activation of Akt166. However, inactivation of PTEN, either by
mutations or posttranslational modifications, uncouples the PI3K-Akt pathway from
extracellular signals, bypassing the requirement for NOTCH1 signaling to maintain cell
growth166.
It is believed that the loss of functional PTEN, as the result of mutations or
posttranslational modifications, may contribute to the GSI-resistance seen in some human
T-ALL cell lines and primary specimens166. The overall lack of response following GSI
treatment is not due to GSI inactivity, because these treatments can still block γ-secretase
activity in GSI-resistance T-ALL cell lines166. As mentioned above, these GSI-resistant
cells lines typically have decreased expression of PTEN166 or the functional activity of
PTEN is loss due to posttranslational modifications198, which results in the constitutive
activation of AKT and appears to be sufficient to relieve the decrease in cell growth
caused by GSI treatments166.

Further, shRNA knockdown of PTEN in GSI-

sensitive/PTEN positive cells could induce GSI resistance. However, this may not be the
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only mechanism for GSI resistance. Medyouf et al.200 reported that the association
between PTEN loss and GSI-resistance could not be detected in both murine leukemias
on PTEN null and wild-type PTEN backgrounds and primary human T-ALL samples.
They suggest that the GSI-resistance seen in human T-ALL cell lines may be due to the
fact that these cell lines were developed from relapsed T-ALLs which that may have
acquired other mechanisms (genetic alterations caused by extensive chemotherapy) to
induce resistance200.

It remains unknown what exactly induces a GSI-resistant

phenotype, but it’s speculated that this may not occur very frequently in the clinic200.
1.10 The Role of microRNAs in ALL
Recent studies have highlighted the increasing complexity of transcriptional
regulation with the discovery of microRNAs (miRs). miRs are small RNA species (1822 nucleotides long) that mediate the expression of target genes with complementary
sequences in their 3’untranslated regions (UTRs)201. miRs are initially transcribed into
primary transcripts in the nucleus202, 203. These pri-transcripts can be polycistronic in that
they encode more than one miR. The pri-microRNA is processed into a 60-70 nucleotide
pre-microRNA transcript by Drosha204.

The pre-miRNA is then transported to the

cytoplasm where it is further processed by Dicer into its mature 22 nucleotide form201, 205.
The mature miR acts mainly through translational repression206,

207

, but may have

transcriptional effects, as well. It binds to complementary target sequences in the 3’UTR
of mRNAs and prevents/disrupts translation208. While a single miR can have several
hundred downstream targets, a single gene can also harbor binding sites for multiple
miRs208-210.
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Altered expression of a limited number of miRs has been found in some
cancers211-214. Differential expression of miRs can be used to distinguish mechanisms of
transformation or tumors of different developmental origins215. In general, tumors and
cancer cell lines typically have lower expression of miRs215. It is believed that miRs
function to regulate and prevent cell division and drive terminal differentiation215. For
example, miR expression profiling of CLL patients demonstrated that the expression
levels of certain miRs could distinguish between cases of CLL with high and low
expression of

ZAP-70 and from those with different mutational status of IgVH216.

Nearly 65% of the cases had deletions in hsa-miR-15a and hsa-miR-16-1, both which
have been shown to down regulate Bcl-2208, 217. A followup study by Calin et al. of 94
CLL patients identified a 13-gene miR signature that was prognostically significant216.
The involvement of miRs in the biology and therapy of T-ALL is poorly understood. It
remains unknown what the total impact of miR expression profiling will be on the
prognosis and treatment of T-ALL.
1.11 Significance of this Study
The long term survival rate for T-ALL patients typically lags behind BP-ALL
patients nearly 20%. This is likely due to the fact that there are few prognostic markers
associated with T-ALL on which to base chemotherapy on.

NOTCH1 has been

implicated as a biomarker with the potential to be a prognostic marker. However, there is
still much unknown about the biology of NOTCH1 and its downstream targets, and their
roles in T-ALL etiology and therapy. This study aims to help determine the overall
prognostic value of NOTCH1 mutations alone, or in combination with mutations in other
key T-ALL genes, FBW7 and PTEN. We will also shed light on whether NOTCH1
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mutations are truly ‘gain-of-function’, as has been previously suggested by the study of a
small number of NOTCH1 mutations. By fully understanding the biology of NOTCH1
signaling in T-ALL, especially its downstream effects, we may begin to identify new
targets that could be prognostically and therapeutically important. Studies such as ours
can aid in identifying new NOTCH1 therapeutic targets and/or give rise to knowledge for
better usage of existing small molecule inhibitors for NOTCH1 in combination with
downstream pathways. Lastly, NOTCH1 signaling is not limited to pediatric T-ALL
patients. Our studies will certainly be applicable to NOTCH1 signaling in adult T-ALL.
NOTCH1 signaling has also been implicated in other cancer types, including both breast
and prostrate cancers. Thus, results of our research into NOTCH1 signaling in pediatric
T-ALLs may also impact the understanding of the biology and therapy of these cancers as
well.
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CHAPTER 2
THE PROGNOSTIC VALUE OF NOTCH1, FBW7 AND PTEN MUTATIONS IN
PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

2.1 Introduction
NOTCH1 signaling is involved in key cellular processes (such as cell fate) by
regulating proliferation, survival and differentiation24, and is crucial for T-cell
commitment in early lymphoid progenitors.

Studies have shown that constitutive

activation of NOTCH1 inhibits B-cell development and is a potent inducer of T-ALL in
murine models24, 79. The initial oncogenic properties of NOTCH1 were first discovered
by the identification of t(7;9)(q34;134.3). This translocation fuses the C-terminal portion
of NOTCH1 to the promoter/enhancer region of TCRβ, resulting in constitutively
activated NOTCH1 signaling in the absence of any ligand. However, this translocation
occurs in less than 1% of all T-ALL cases.
In 2004, Weng et al. discovered activating NOTCH1 mutations in more than 50%
of pediatric T-ALL patients. Such mutations were confined to ‘hot-spot’ regions within
the HD and PEST domains.

These mutations are described as ‘gain-of-function’

mutations, as they are believed to result in constitutively active ICN and increase the
activity of NOTCH1 signaling125.

Mutations within the HD domain destabilize the

heterodimerization of the receptor, making it more susceptible to cleavage by γsecretase125, 127, 218, whereas mutations in the PEST domain increase the half-life of ICN
and reduce protein turnover125, 127, 218, 219. These mutations are unlikely to be all ‘gain-offunction’ mutations. In the 2004 report125, single L to P amino acid substitutions in the
HD domain at positions 1575, 1594 or 1601 yielded a 3- to 9-fold increase in reporter
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activity. A PEST domain deletion at position 2471 yielded a 1.5- to 2-fold increase in
reporter activity. Even more interesting was the 20- to 40-fold increase in reporter
activity seen when each of the above HD mutations were in cis with the PEST domain
deletion.

Collectively, these results suggest that not all NOTCH1 mutations are

activating and in the same degree.
NOTCH1 mutations are considered to be ideal biomarkers because they are
acquired in malignant blasts and disappear upon remission131. However, the prognostic
value of these mutations remains controversial.

Some reports claim that NOTCH1

mutations are associated with favorable prognosis, while other reports claim these
mutations indicate an unfavorable prognosis91, 131, 132, 139, 140, 142. It also remains unclear
what role NOTCH1 mutations may play in the development of relapse. Other factors
such as FBW7 mutations, which result in prolonged NOTCH1 signaling, can have a
significant impact on the role of NOTCH1 signaling in progression of T-ALL and its
therapeutic response.
PTEN inactivation, whether by mutations or posttranslational modifications, likely
contributes to T-ALL development and progression and influences overall responses to
chemotherapy. Inactivation of PTEN, by homozygous deletion or mutations in many
tumors, results in constitutive Akt signaling, inhibition of TSC1/TSC2182, and consequent
mTOR1 activation. Results from cancer cell lines and tumor xenografts establish a
strong association between the losses of PTEN function and the antiproliferative effects
of the macrolide rapamycin, an effective inhibitor of mTOR1182, 220. Losses of PTEN are
associated with the pathogenesis of T-cell tumors based on PTEN knockout mouse
models190, 221, 222. Conditional PTEN deletions in mouse hematopoietic stem cells lead to
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myeloproliferative disorder, followed by T-ALL223. Recent studies indicate that PTEN
mutations and losses of protein occur at high frequencies in primary T-ALLs with no
associations with T-ALL oncogenic subgroups166. In T-ALL cell lines, PTEN mutations
were associated with increased Akt phosphorylation and GSI resistance166. To date, the
prognostic value of PTEN mutations in T-ALL has not been studied extensively.
Relapse is the most common cause of off-therapy events and can account for
nearly 90% of treatment failures in ALL105. The rate of relapse is dependent upon the
immunophenotypic subtype, genetic subtype and/or other risk classifications of ALL47, 48,
224

. Relapse typically occurs within the first 3-5 years following diagnosis but can also

arise 10 or more years post diagnosis2. Relapse can arise from the outgrowth of residual
leukemic cells that escape initial chemotherapy and are below the limit of detection at the
time remission was declared, or very rarely relapse can result from a new secondary
leukemia that may or may not be a direct side effect of chemotherapy. Relapse typically
occurs in the bone marrow and/or extramedullary tissues, including CNS and testis2.
Extramedullary relapse is thought to arise from leukemic cells that are ‘hidden’ from
chemotherapy in sanctuary sites225, whereas bone marrow relapse essentially develops in
much the same way as the initial leukemia. The bone marrow is the most common site of
relapse and has the worst prognosis226. It is generally accepted that relapsed ALL is
morphologically and immunophenotypically similar to diagnostic ALL2, although
relapsed disease may also exhibit new genetic abormalities227. It is believed that relapse
arises from (i) induction of resistance via acquisition of new genetic alterations after
diagnosis, (ii) selection and expansion of an already present resistant sub-population at
diagnosis, or very rarely as (iii) a secondary, de novo ALL26-28. A more comprehensive
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understanding of the etiology of relapse may lead to better therapeutic strategies that may
prevent relapse from occurring.
Studies in this chapter were designed to explore the potential prognostic
significance of NOTCH, FBW7 and PTEN mutations, individually and in combination,
and what implications these may have on the development of relapse. They also address
the functional activity of NOTCH1 and FBW7 mutations (both individually and in
combination) in vitro to determine if they are indeed activating, and in situ to assess the
net downstream effects of activated NOTCH1 signaling resulting from these alterations
in cells.
2.2 Materials and Methods
2.2a Patient Specimens
2.2a i Patient Specimens for Prognostic Studies
Forty-seven T-cell ALL patient specimens (including 24 patients who did not fail
treatment [‘not failed’] and 23 patients who failed treatment [‘failed’]) were obtained
from the Children’s Oncology Group (COG) ALL cell bank and used for this study.
Patients were treated on Pediatric Oncology Group (POG) protocols including POG 8704
(14 failed, 14 not failed patients), 9086 (4 failed, 3 not failed patients), 9295 (1 failed
patient), 9296 (2 failed, 1 not failed patient), 9297 (2 failed, 3 not failed patient) and 9398
(1 failed, 2 not failed patients). Patients in the ‘not failed’ group were children who
remained in remission for 4 or more years following diagnosis, and patients in the ‘failed’
group were children who suffered bone marrow relapses within 4 years of diagnosis.
Major chemotherapy drugs used were L-asparaginase, doxorubicin, 6-mercaptopurine,
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methotrexate, prednisone and vincristine. Patients who died in remission within 4 years
of diagnosis were excluded from this study.
2.2a ii Patient Specimens for Relapse Studies
Paired diagnostic and relapsed bone marrow aspirate slides and/or cryopreserved
cells from 11 T-ALL pediatric specimens were obtained from Children’s Hospital of
Michigan. All relapses occurred in the bone marrow. This study included patients who
died during relapse.
2.2b Amplifying and Sequencing Mutations
2.2b i Amplifying and Sequencing Mutations in Prognostic Studies
Sample handling and data analysis protocols were approved by the Committee on
Investigation Involving Human Specimens at Wayne State University. Leukemic blasts
were purified by standard Ficoll-Hypaque density centrifugation. Total RNAs were
extracted from primary ALL lymphoblasts using the RNEasy Midiprep Kit (Qiagen;
Valencia, CA). cDNAs were prepared from 1µg RNAs using random hexamers and a
RT-PCR kit (PerkinElmer; Boston, MA), and purified with the QIAquick PCR
Purification kit (Qiagen).
Mutations in NOTCH1 (HD and PEST domain) and PTEN (entire coding
sequence) were identified in cDNAs by nested PCR methods. Primer sequences and PCR
conditions are summarized in Table 2. FBW7 mutations were identified either in cDNAs
or in genomic DNAs by amplifying sequence including exons 11, 12 and 14, previously
reported as mutational ‘hotspots’125. PCR products were separated on 1% agarose gels
with ethidium bromide and purified with a gel extraction kit (Marligen Biosciences;
Ijamsville, MD). Alternatively, PCR products were directly purified using the QIAquick
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Table 2: Primer Sequences and PCR Conditions Used to Identify Mutations in
NOTCH1, FBW7 and PTEN in the 47 Pediatric T-ALL Cohort
GENE

NOTCH1

FBW7

PTEN

ANNEALING CYCLES
PRIMER
PRIMER SEQUENCE
(°C)
POSITION
5’GCGGTGACTGCTCCCTCAACTTCAAT
4430
Primary
58°C
35
5’GGAACTTCTTGGTCTCCAGGTCCTCGTC
5446
5’GCCAGTGCAACCCCCTGTACGACCAGTA
4580
HD
Nested
61°C
38
5’GTCGTCCATGAGGGCACCGTCTGAAG
5402
5’GTCACCCCATGGCTACCTGTCAGAC
6615
Primary
58°C
35
5’CGTAGGAAAACCCTGGCTCTCAGAACTT
7926
5’ GGAGGGGCCCTGAATTTCACTGTG
6874
PEST
Nested
61°C
38
5’ TGTGTTTTAAAAAGGCTCCTCTGGTCGG
7747
5’GATAGAACCCCAGTTTCAACGAGAC
962
8
56°C
35
Primary
5’ ACTAACAACCCTCCTGCCATCATA
Nested
13
1674
5’TCTCGAGATGCCACTCTTAGGGT
12
1581
56°C
35
Primary
5’ACGCCTCTCTTGTCAGTTATGGTTT
14
2456
5’ATTTTCTGAAGAGCCAAACA
Intron
52°C
35
11
Primary
5’CTAATTTAAGAGCACACTGTCACTA
Intron
5’TCCCAACTTCCCATTCCCTTAT
Intron
54°C
35
12
Primary
5’ CATAGCAAACTTAGAGCCCCAAAG
Intron
5’ACCTAGTCACATTGGAGAGTG
Intron
54°C
35
14
Primary
5’TCTTCTTTTCCTTCTTAGTCTGTAG
Intron
5’ATGGTTCTGAGGTCCGCTCTTTTTC
6
670
Primary
57°C
35
5’CCCTGTCTCCACATCCCAAACA
13
1841
5’CGTTCGGAGGATTATTCGTC
5’UTR
762
54°
35
Primary
5’GAAACCTCTCTTAGCCAACTGC
3’UTR
2681
5’CAGCTACCGCCAAGTCCA
5’UTR
925
56°C
38
Nested
5’ATAAAACGGGAAAGTGCCATCT
3’UTR
2510
5’CCAGTGGCACTGTTGTTTCACA
1599
CDS
5’CAGGTAACGGCTGAGGGAACTC
CDS
1755
N/A
N/A
5’AGAGGCGCTATGTGTATTATT
Sequencing
CDS
512
5’ TTTGACGGCTCCTCTACTGT
CDS
1048
The position of each primer is based upon the database sequences for NOTCH1 (NM_017617.3), FBW7
(NM_033632.2), and PTEN (NM_000314.4). Abbreviations: CDS, coding sequence; NA, not applicable;
UTR, untranslated region
EXON/
DOMAIN

PCR
TYPE
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cDNA purification kit (Qiagen) and sequenced in both directions with M13 forward and
reverse primers (these primer sites were located on the primers used for PCR) or genespecific primers at either the Wayne State University Applied Genomics Technology
Core or Genewiz, Inc. (South Plainfield, NJ). For a small number of samples, PCR
products were subcloned into a TA-cloning vector [pCRII-TOPO (Invitrogen; Carlsbad,
CA)] and transformed into One Shot® MACH1T1 competent cells.

Plasmids were

isolated using the Wizard® Plus Mini Prep DNA purification system (Promega; Madison,
WI) for DNA sequencing.
2.2b ii Amplifying and Sequencing Mutations in Relapse Study
Total RNAs and genomic DNAs (gDNAs) were isolated from cyropreserved
lymphoblasts using Trizol® (Invitrogen) and the recommended protocol. cDNAs were
amplified as described in 2.2b.1. gDNA was isolated from bone marrow aspirate slides
with Wright-Giesma staining by first immersing the slide in p-xylene for 2-3 days to
remove the cover slips. Secondly, the cellular material was scraped off the slides into a
microcentrifuge tube. Lastly, gDNA was extracted using the QIAamp DNA Mini Kit
(Qiagen) according to the manufacturer’s protocol.

For those specimens in which

cDNAs were amplified, mutational analysis of NOTCH1, FBW7 and PTEN was
conducted as described in 2.2b.1. For specimens obtained from bone marrow aspirate
slides, gDNAs were PCR amplified with intron primers flanking the HD and PEST
domains of NOTCH1, intron primers designed to amplify exons 1-9 of PTEN, and
primers amplifying exons 11-14 of FBW7. Primer sequences and PCR conditions are
summarized in Table 3. Amplicons were either sequenced directly or subcloned into a
T/A cloning vector prior to sequencing (as previously described).
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Table 3: Primer Sequences and PCR Conditions Used to Identify NOTCH1, FBW7
and PTEN Mutations in Diagnosis/Relapse Specimens
Gene

NOTCH1

FBW7

PTEN

Primer
Name
FHD1
RHD1
FHD2
RHD2
PDF
PDR
FBW7/F962
FBW7/R1674
FBW7/F1581
FBW7/R2456
FBW7-EX11F
FBW7-EX11R
FBW7-EX12F
FBW7-EX12R
FBW7-EX14F
FBW7-EX14R
FBW7/F670
FBW7/R1841
PTEN1F
PTEN1R
EX2F/PTEN
EX2R/PTEN
EX3F/PTEN
EX3R/PTEN
EX4F/PTEN
EX4R/PTEN
EX5F/PTEN
EX5R/PTEN
EX6F/PTEN
EX6R/PTEN
EX7F/PTEN
EX7R/PTEN
EX8F/PTEN
EX8R/PTEN
EX9F/PTEN
EX9R/PTEN

Primer
Position
Intron
Intron
Intron
962
1674
1581
2456
Intron
Intron
Intron
670
1841
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron

Primer
Sequence
5’ CGAGTGGGACGGGCTGGACTG
5’ AAAGGGTGTGGCTGTGGGGTCA
5’ TCCCAGCCCCTCTCTGATTGTC
5’ CGGACGGCAACGCTCACAC
5’ GTCTCCGTCCGTGCCCCTCAACCAC
5’ GTCGGCCCTGGCATCCACAGAGC
5’ GATAGAACCCCAGTTTCAACGAGAC
5’ ACTAACAACCCTCCTGCCATCATA
5’ TCTCGAGATGCCACTCTTAGGGT
5’ ACGCCTCTCTTGTCAGTTATGGTTT
5’ ATTTTCTGAAGAGCCAAACA
5’ CTAATTTAAGAGCACACTGTCACTA
5’ TCCCAACTTCCCATTCCCTTAT
5’ CATAGCAAAACTTAGAGCCCCAAAG
5’ ACCTAGTCACATTGGAGAGTG
5’ TCTTCTTTTCCTTCTTAGTCTGTAG
5’ ATGGTTCTGAGGTCCGCTCTTTTTC
5’ CCCTGTCTCCACATCCCAAACA
5’ GCCGTTCGGAGGATTATTCGT
5’ AGTTCCGTCTAGCCAAACACACC
5’ TTGTTTTGATTTTTGGTTTTTGAC
5’ GTATCCCCCTGAAGTCCATTAG
5’ AGGGGTATTTGTTGGATTATTTATT
5’ CCCTAACAGCTTTTTCAGTCAAT
5’ TTTTATTATTATAATATGGGGGTGA
5’ CTATCGGGTTTAAGTTATACAACAT
5’ GTATGCAACATTTCTAAAGTTACCT
5’ TTGTCAATTACACCTCAATAAAAC
5’ CCCAGTTACCATAGCAATTTAGTGA
5’ CTTCTTTAGCCCAATGAGTTGAAC
5’ TTGCAGATACAGAATCCATATTTCG
5’ TATAATGTCTCACCAATGCCAGAGT
5’ GAAAATGCAACAGATAACTCAGAT
5’ ATCACATACATACAAGTCAACAACC
5’ GATCATGTTTGTTACAGTGCTTA
5’ CCATTTTCAGTTTATTCAAGTTTAT

Annealing
(°C)

Cycles

65

35

62

35

62

35

56

35

56

35

52

35

54

35

54

35

55

35

56

35

51

35

51

35

51

35

51

35

51

35

51

35

51

35

51

35

The position of each primer is based upon the database sequences for NOTCH1 (NM_017617.3), FBW7
(NM_033632.2), and PTEN (NM_000314.4).
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2.2c Real-Time RT-PCR Analysis of Gene Expression Profiles
Analyses of gene expression levels were performed in a blinded manner.
Transcript levels for 22 chemotherapy-related genes, PTEN, downstream NOTCH1
targets (HES1, DTX1, cMYC) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were measured with a LightCycler real-time PCR machine (Roche;
Indianapolis, IN). The primer sequences and PCR conditions for the 22 chemotherapyrelated genes are summarized in Table 4. Reactions contained 2 µl of purified cDNA or
standard plasmid, 4 mM MgCl2, 0.5 µM each of sense and antisense primers, and 2 µl of
FastStart DNA Master SYBR Green I enzyme-SYBR reaction mix (Roche), as
described228. Specificity of the amplifications was confirmed by melting curve analysis
and comparisons to standard templates. For each gene of interest, external standard
curves were constructed using serial dilutions of linearized templates, prepared by
amplification from cDNA templates, subcloned into a TA-cloning vector and restriction
digested with KpnI. Transcript levels for genes of interest were normalized to GAPDH
transcripts.
2.2d NOTCH1 and FBW7 Mutagenesis
The wild-type NOTCH1 expression construct in pcDNA3 was a gift from Dr.
Spyros Artavanis-Tsakonas (Harvard University; Cambridge, MA). Full-length wildtype FBW7 cDNA (variant 1; NM_033632.2) was amplified from the T-ALL cell line
MOLT4 (American Type Culture Collection; Rockville, MD) using primers located in
the 5’ untranslated region (UTR) (TTCACGGTACCCGAAGGAGGAAGGGAACCAA
CC; bold sequence indicates Kpn1 site) and 3’UTR (TTCACGAATTCAGGGGGAAG
GGCAGGGAGTA; bold sequence indicates EcoRI site). Following PCR amplification
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Table 4: Real-Time PCR Primers and Conditions for 22 Chemotherapy-Related
Genes
GENE

PRIMER SEQUENCES

SIZE
(BP)

ANNEALING
(°°C)

GENBANK
ACCESSION

Forward: 5’ACCCTAATCCCTGCCCAGAG
186
60
NM_004996
Reverse: 5’CGCATTCCTTCTTCCAGTTC
Forward: 5’ACGGGCACATCACCATCAAG
171
63
NM_000392
Reverse: 5’CTCCAGGCAGCATTTCCAAG
Forward: 5’CGCCTGTTTTTCTGGTGGTT
164
63
NM_020038
Reverse: 5’TTGTGTCGTGCCGTCTGCTT
Forward: 5’GCGGCTGACGGTTACCCTCTT
189
60
NM_005845
Reverse: 5’TCTGATGCCTTATCCCAAAAAGCAGT
Forward: 5’CCAAGCTGACCCCCAAAATGAAAAA
175
63
NM_005688
Reverse: 5’TGGATGTGCTTGCCTTCTTCCTCTTC
Forward: 5’GGTGGAGGCAAATCTTCGTTATTAGA
154
59
AF098951
Reverse: 5’GAGTGCCCATCACAACATCATCTT
Forward: 5’TCGGAAGAACACAGATAGCGTGGTGA
161
60
NM_133436
ASNS
Reverse: 5’TGCGCGGAGAACATCAAACAAATAGAG
Forward: 5’CTGCACCTGACGCCCTTCACC
119
61
BC027258
BCL2
Reverse: 5’CACATGACCCCACCGAACTCAAAGA
Forward: 5’GATCCCCATGGCAGCAGTAAAGCAAG-3’
164
63
Z23115
BCL-XL
Reverse: 5’CCCCATCCCGGAAGAGTTCATTCACT-3’
Forward: 5’AATGAAAAGGCCCCCAAGGTAGTTATCC
112
55
NM_002467
c-MYC
Reverse: 5’GTCGTTTCCGCAACAAGTCCTCTTC
Forward: 5’CAGCCGCCTGGGAAGATGGAGTT
104
60
NM_004416
DTX-1
Reverse: 5’TGGATGCCTGTGGGGATGTCATAGAC
Forward: 5’CATGGTTGGTTCGCTAAACTGC
126
60
BC071996
DHFR
Reverse: 5’GAGGTTGTGGTCATTCTCTGGAAATA
Forward: 5’GCTGCAGGTGGAGGACTTGGAC
109
60
NM_004957
FPGS
Reverse: 5’CAGGCCATAGCTTCGGAGGATACATT
Forward: 5’AACGGGAAGCTTGTCATCAATGGAAA
194
60
NM_002046
GAPDH
Reverse: 5’GCATCAGCAGAGGGGGCAGAG
Forward: 5’GCTTGCTCAGGAGAGGGGAGATGT
133
62
X03225
GCR
Reverse: 5’CAAAAGTCTTCGCTGCTTGGAGTCTG
Forward: 5’GAGTCTGCAGGTGCGAGAGTTGTA
144
60
NM_003878
GGH
Reverse: 5’TTTGGCCACTTTAGCATAATCTGAGC
Forward: 5’CCAAGCTGGAGAAGGCGGACATTC
165
61
NM_005524
HES1
Reverse: 5’ACGTGGACAGGAAGCGGGTCAC
Forward: 5’GCTATAAATTCTTTGCTGACCTGCTG
140
62
NM_000194
HPRT
Reverse: 5’AATTACTTTTATGTCCCCTGTTGACTGG
Forward: 5’GTGGAGAAGCAGGTGCCCGTGGAA
175
64
NM_003056
hRFC
Reverse: 5’CGTGACCTGCTCCCGCGTGAAGTT
Forward: 5’TGGCCACCAATACTTCTGCTCCTGAT
172
60
NM_002375
MAP4
Reverse: 5’GGGCCGGCTGTTTTAGTGACTGC
Forward: 5’CAGGAACCTGTATTGTTTGCCACCAC
188
60
NM_000927
MDR1
Reverse: 5’TGCTTCTGCCCACCACTCAACTG
Forward: 5’CCAGTGGCACTGTTGTTTCACA
178
60
NM_000314
PTEN
Reverse: 5’CAGGTAACGGCTGAGGGAGCTC
Forward: 5’AGCGGTTGAGATGAAATGGTTTGC
181
62
BC009596
TPMT
Reverse: 5’ACAGTACAATGAAATGTTCCCCGAAGAA
Forward: 5’TGAAGAAGACAGCAGCAAAAAGTCAGT
189
60
NM_001067
TOP2A
Reverse:5’AAAATTAGAGTCAGAATCATCAGAAGTGG
Forward:5’ACATCCAAAACAACAAGCAAGAAACCGA
105
62
NM_001068
TOP2B
Reverse:5’GCAGAGAAGGTGGCTCAGTAGGGAAGTCT
Forward: 5’TTGGCCAGATCTTTAGACCAGACAAC
122
62
NM_178014
TUBB1
Reverse: 5’CCGTACCACATCCAGGACAGAATC
Forward: 5’GCTCAGGGGCCTTTGGACATCTCTT
148
63
NM_006086
TUBB3
Reverse: 5’TTTTCACACTCCTTCCGCACCACATC
Abbreviations are: MRP, multidrug resistance-associated protein; ABCG2 (BCRP), breast cancer resistance protein; ASNS,
asparagine synthetase; BCL2, B-cell leukemia/lymphoma 2; BCL-XL, B-cell leukemia/lymphoma X long isoform; c-MYC,
Myelocytomatosis viral oncogene homolog; DTX, Deltex1; DHFR, dihydrofolate reductase; FPGS, folylpolyglutamate synthase;
GAPDH, Glyceraldehye-3-phosphate dehydrogenase; GCR, alpha-glucocorticoid receptor; GGH, gamma-glutamyl hydrolase;
HES1, Hairy and enhancer of split; UTR, Untranslated region; HPRT, hypoxanthine phosphoribosyl transferase; hRFC, human
reduced folate carrier; MAP4, microtubule-associated protein 4; MDR1, multidrug resistance 1; PTEN, phosphatase and tensin
homolog; TPMT, thiopurine s-methyltransferase; TUBB1, tubulin beta; TUBB3, tubulin beta 3.
ABCC1
(MRP1)
ABCC2
(MRP2)
ABCC3
(MRP3)
ABCC4
(MRP4)
ABCC5
(MRP5)
ABCG2
(BCRP)
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and subcloning into pCRII-TOPO (Invitrogen), FBW7 constructs were digested with
KpnI and EcoRI, and purified with the QIAquick Gel Extraction Kit (Qiagen). Digested
FBW7 was subcloned into pcDNA3 and transformed into JM109 competent cells
(Promega). FBW7-pcDNA3 constructs were isolated with the Wizard® Plus Midiprep
DNA purification system (Promega). Site-directed mutagenesis of the HD and PEST
domains of wild-type NOTCH1 and WD40 domains of FBW7 used the QuikChange
Lightning site-directed mutagenesis kit (Stratagene; La Jolla, CA), following the
manufacturer’s protocol with these modifications: (a) 100 ng of wild-type NOTCH1 or
FBW7 (both in pcDNA3) were used as template; (b) extension time was 30 sec/kb at
68°C; and (c) DpnI digestions were for 10 minutes. Mutant plasmids were transformed
into XL10-Gold ultracompetent cells and (d) LB-ampicillin agar plates were incubated at
37°C for >24 h to prevent recombination. Mutant constructs were transformed into
JM109 competent cells to obtain higher copy number plasmids. Plasmids were isolated
and the mutants were confirmed by DNA sequencing.
2.2e Generation of HES1 Promoter Reporter Construct and Reporter Gene Assays
A construct with an artificial luciferase reporter gene under the control of a HES1
promoter containing CSL/ICN1 binding sites (HES1-Luc) in pGL3-Basic (Promega) was
prepared as follows. The promoter region of the human HES1 gene between positions 942 and -158 (NM_005524) from the translational start site was isolated by PCR from
gDNA prepared from CMK16 cells (DSMZ; Braunschweig, Germany) using forward
(5’TTCACGCTAGCGTCTAAGGCCCCAAATCCAAACGAG) and reverse
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(5’TTCACCTCGAGCAGTAGCGCTGTTCCAGGACCAAG) primers (bold sequences
indicate NheI and XhoI restriction sites, respectively). The amplified fragment was
digested with NheI and XhoI and subcloned into pGL3-Basic vector (Promega).
Human U20S osteosarcoma cells (American Type Culture Collection) were
cultured at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (Hyclone; Logan, UT), 1% penicillin (100 U/mL)/streptomycin
(100 µg/ml) (Invitrogen), and 1% L-glutamine (200 mM) under 5% CO2.
NOTCH1 and FBW7 expression plasmids were transiently transfected into U20S
cells with HES1-Luc and pRL-SV40, using Lipofectamine Plus (Invitrogen). Briefly, 3.2
x 105 U20S cells were seeded per well (35 mm) of a six well plate, allowed to adhere
overnight and then co-transfected with 1 µg of HES1-Luc, 30 ng of pRL-SV40
(Promega), and wither 0.9 µg of wild-type or mutation NOTCH1-pcDNA3 constructs or
ICN1-pcDNA3 (provided by Dr. Lucio Miele, Loyola University; Chicago, IL). Total
DNA was maintained constant by adding empty pcDNA3 plasmid (Invitrogen). For the
FBW7-NOTCH1 co-transfections, wild-type and mutant FBW7-pcDNA3 constructs (0.9
µg) were co-transfected into U20S with wild-type and mutant NOTCH1-pcDNA3
constructs (0.9 µg) with 500 ng of HES1-Luc/30 ng of pRL-SV40. For both series, 48 h
post-transfection, the cells were lysed and luciferase activities were assayed using a Dual
Luciferase reporter assay system (Promega) on a Turner Designs 20/20 luminometer.
Relative luciferase activities of the cell lysates were normalized to Renilla luciferase
activity (encoded by pRL-SV40). Data are reported as mean values plus/minus SEM
from replicate assays.
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2.2f Detection of Relapse Clones at Diagnosis
Real time PCR and melting curve analysis with genomic DNAs from paired
diagnostic-relapse T-ALL specimens was used to determine whether newly identified
relapse T-ALL clones were present at the time of diagnosis as a minor subclonal
population. NOTCH1 hybridization probes (TIB MOLBIOL; Berlin, Germany) were
designed to detect mutant NOTCH1 sequence in diagnostic specimens.

The probe

sequences are summarized in Table 5. The genotype analysis was performed on a
LightCycler real time PCR machine (Roche) with gene-specific primers and
3’fluorescein-labeled and 5’LC-red640-labeled hybridization probes.

Samples were

amplified over 35 cycles, after which melting curves for the products were analyzed at
640 nm from 40°C to 80°C at a rate of 0.3°C/s.
2.2g Statistical Methods
Patient statistical analysis was performed by Dr. M. Devidas of the Children’s
Oncology Group (COG) Statistical Office in Gainesville, FL.

Data analyses were

performed using the SAS System (SAS Institute Inc. SAS OnlineDoc® 9.1.3. Cary, NC:
SAS Institute Inc, 2005) and R (R Foundation for Statistical Computing,;Vienna, Austria.
ISBN 3-9000051-07-0, URL http://www.R-project.org. 2005), or GraphPad Prism 4.0.
For analyses of overall NOTCH1 signaling, transcript levels for HES1, DTX1 and cMYC
were categorized into low and high levels, respectively, corresponding to values below
and above the median values.

The non-parametric Wilcoxon test was used for

comparisons of transcript levels between various subgroups (cases versus controls,
NOTCH1 mutant versus non-mutant group, high and low WBC, high versus low
HES1/DTX1/cMYC transcripts). The associations between high/low transcript levels of
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Table 5: Sequence of the NOTCH1 Hybridization Probes
Probe

Probe Type

Probe Name

Sequence

Annealing
(°C)

Notch1 F1
5’ GGGTAGCTGCTGTCAGACC
PCR
Amplification
Notch1 R1
5’ CCTCGATCTTGTAGGGGATGT
T5039A
57
Sensor
5’ GCCGGTTGTCAATCTCCAGGTAG
Anchor
5’ CGATGGAGCTGGGCGGACAA
T5153CF1
5’ TCCTCGCAGTGCTTCCA
PCR
Amplification
T5153CR1
5’ CAAACAGCCAGCGTGTCT
T5153C
57
Sensor
5’ CCTACAAGACCGAGGCCGTG
Anchor
5’ AGAGTAAGTGTGGCCCCATCCCGG
The position of each NOTCH1 primer is based upon the database sequences for NOTCH1 (NM_017617.3).
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a gene and outcome or prognostic factors such as age group or WBC group were tested
using Fisher’s Exact test. The non-parametric Spearman’s correlation coefficient was
used to measure the associations between NOTCH1 target genes. The paired t test was
used to make comparisons between the luciferase activities associated with the NOTCH1
mutants and wild-type NOTCH1.
2.3 Results
2.3a Identification of NOTCH1 Mutants in Primary T-ALL Specimens
Although significant improvements have been documented in the treatment
outcome of T-ALL in children, T-ALL remains an aggressive disease with a substantially
poorer prognostic outlook than that for BP-ALL. Following reports of high frequency
mutations in the NOTCH1 receptor125, 131, 132 involving the HD (positions 4710 to 5163)
and PEST (positions 6930 to 7665) domains [position numbers based upon NOTCH1
sequence (NM_017617.3)], we became interested in the prognostic significance of
mutant NOTCH1 and possible explanations for disparate reports of both good and poor
prognoses for T-ALL patients with NOTCH1 mutations91,

125, 131, 132, 135, 140

. A well-

characterized cohort of 47 pediatric T-ALLs with documented treatment outcomes was
used to explore this clinically important question. The 47 children included 38 boys and
9 girls diagnosed with T-ALL, 23 of whom relapsed within 4 years of diagnosis (failed)
and 24 of whom remained in remission for 4 or more years after diagnosis (not failed).
Patient ages ranged from 1.8 to 19.9 years (median = 7.48 years) and WBCs ranged from
8.2 to 999 x 109 cells/L (median = 240 x 109 cells/L) (Table 6).
RNAs from the 47 T-ALL specimens were reverse transcribed and cDNAs were
PCR amplified across the NOTCH1 HD and PEST domains. The amplicons were
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Table 6: Characteristics of the 47 Pediatric T-ALL Specimens
GENDER

WBC (x109 cells per l)

Age (years)
N

Minimum

Median

Mean

s.d.

Maximum

N

Minimum

Median

Mean

s.d.

Maximum

Male

38

1.83

7.48

8.66

4.86

19.86

38

8.20

267.50

335.86

262.81

999.90

Female

9

4.13

6.45

6.49

2.26

11.62

9

20.00

171.80

242.77

224.12

680.00

Total

47

1.83

7.15

8.24

4.54

19.86

47

8.20

240.00

318.03

256.25

999.90

Abbreviation: s.d., standard deviation
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sequenced in both directions with M13 primers to identify potential HD and PEST
mutations. In a few cases, amplicons were subcloned into a T/A cloning vector and
individual plasmid clones were isolated for DNA sequencing. Twenty-five samples
showed a high frequency polymorphism (C5094T) in the HD domain that was silent
(GAC and GAT both encode aspartic acid). NOTCH1 mutations resulting in modified
primary sequence were detected in16 patients (9 HD, 4 PEST, 3 HD and PEST) and wildtype NOTCH1 sequences were detected in 31 patients (Table 7). NOTCH1 mutations
included single point mutations, deletions and insertions in the HD and PEST domains
that variously resulted in amino acid substitutions and premature translation terminations
(Table 7). With few exceptions (V1671I, 2514 RVP*Stop, 2459*Stop and 2503*Stop),
these mutations are unique from those previously described as ‘gain-of-function’ in TALL125, 132. The frequency (34%) of NOTCH1 mutations in our analysis is somewhat
lower than that originally reported in pediatric T-ALL125, and may reflect the unique
features of our T-ALL cohort (~50% of patients relapsed). Nonetheless, similar
frequencies have been reported in both pediatric and adult T-ALL patients in other
studies125, 131, 132, 138.
For our 47 patient cohort, there were no associations between age or WBC and
the presence of NOTCH1 mutations. In contrast to recent reports that the presence of
NOTCH1 mutations were good prognostic factors in T-ALL91,

132

, no statistically

significant differences were seen in frequencies of mutations between patients who
relapsed (9 of 23 patients harbored NOTCH1 mutations) and patients who did not (7 of
24 patients harbored NOTCH1 mutations; p=0.5469, by Fisher’s exact test) (Figure 5A).
Interestingly, for the 28 patients treated on a single (POG8704) protocol (14 failed, 14 not
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Table 7: Summary of NOTCH1 Mutations in the 47 Pediatric T-ALL Specimens
Sample

DNA Mutations
HD Domain
PEST Domain

Amino Acid
Changes

1

INS4827(CCCCAACCT); G4828A

Normal

INS1609(PQP); A1610T

2

G4898T; C5094T

Normal

R1633L

3

G4966A; C5094T

A7233G; DEL7541-7542(CT)

G1654S; P2514R; E2515V;
S2516P; 2517*

4

G4985T; C5094T

C7507T

R1662L; Q2503*

5

G5011A; C5094T

T7515G

V1671I

6

G4948A

Normal

A1650T

7

Normal

C7375T

Q2459*STOP

8

Normal

9

G4893T

10

G5011A

T7515G

V1671I

11

G4976A; C5094T

Normal

G1659D

12

DEL5024-5026(TCG); C5094T

Normal

DEL 1676(V)

13

Normal

C7322T; DEL 7541-7542(CT)

A2441V; P2514R; E2515V;
S2516P; P2517*

14

G4900T

Normal

A1634S

C7530T

INS1588(SFHFLPRLPHNS)

INS7313(CT)

INS1588(SFHFLPRLPHNS);
S2451*

15
16

INS4776(CTGCCGCGCCTTCCCCA)
with DUP of 4758-4776
(CAACAGCTCCTTCCACTTC)
INS4776(CTGCCGCGCCTTCCCCA)
with DUP of 4758-4776
(CAACAGCTCCTTCCACTTC)

G7392A; T7515A; DEL 75187537
(GCACCCCTTCCTCACCCCGT);
INS7518(TCTCCTACC)
DEL 7531-7541
(ACCCCGTCCCC)

E2506D; H2507L; P2508L;
F2509P; L2510P; T2511*
2511*

The position of NOTCH1 mutations is based upon the database sequences for NOTCH1 (NM_017617.3).
Abbreviations are: HD, Heterodimerization; INS, Insertion; DEL, Deletion; DUP, Duplication; *, Stop
codon; nt, Nucleotide; N/A, Not Available; UTR, Untranslated Region; WT, Wild type; ∆, changed
sequence.
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Figure 5: Association of NOTCH1 Mutations, Alone or in Combination with FBW7
Mutations, with Treatment Outcome
A.
20

Wild-Type NOTCH1 (n=31)
Mutant NOTCH1 (n=16)

Patient Number

17/24
14/23

P=0.5469
9/23

10

7/24

0
Failed

Not Failed

Treatment Outcome

B.
20

Wild-Type (n=29)
Mutant (n=18)

Patient Number

16/24
13/23

P=0.5556

10/23
10

8/24

0
Failed

Not Failed

The associations of NOTCH1 mutations, alone and in combination with FBW7 mutations, with treatment
outcomes were tested using Fisher’s Exact test. (5A) There was no difference in the frequency of
NOTCH1 mutations between those patients who failed treatment (9 of 23 patients harbored NOTCH1
mutations) and those who did not fail treatment (7 of 24 patients harbored NOTCH1 mutations; p=0.5469).
(5B) Likewise, there is no difference in the frequency of NOTCH1 mutations and FBW7 mutations
between those patients who failed treatment (10 of 23 patients had either NOTCH1 and/or FBW7
mutations) and those who did not fail treatment (8 of 24 patients had either NOTCH1 and/or FBW7
mutations; p=0.5556). Patients who failed treatment relapsed with in 4 years of treatment. Patients who
did not fail treatment were in remission at least 4 years following treatment.
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failed), there was a decrease in the frequency of NOTCH1 mutations in patients who
relapsed (3 of 14 patients harbored NOTCH1 mutations) compared to those who
responded to treatment (6 of 14 patients harbored NOTCH1 mutations). However, this
difference was still not statistically significant (p=0.4197).
We reasoned that our inability to establish statistically significant associations
between relapse and mutant NOTCH1 in our 47 patient cohort could be due to (i) various
levels of overall signaling, resulting from different activating potencies for the assorted
NOTCH1 mutants. Other factors may also be important such as (ii) high frequency
mutations in the FBW7 ubiquitin ligase that impact steady state levels of ICN
independent of the NOTCH1 mutational status91, 92, or (iii) decreased expression (due to
HES1 and cMYC) and/or inactivating mutations involving the PTEN gene, resulting in
increased AKT signaling166. Finally, (iv) the T-ALL specimens were from patients
treated with different protocols and aberrant NOTCH1 signaling may impact sensitivities
to various chemotherapy drugs to different extents.
2.3b Identification of FBW7 Mutations in Primary T-ALL Specimens
Since

high

frequency

mutations

in

the

E3-ubiquitin

ligase

FBW7

[NM_001013415.1] substrate binding domain were reported in up to 30% of pediatric TALL patients91-93, the 47 T-ALL specimens were analyzed for mutations in the FBW7
gene. cDNAs from 44 specimens were amplified across exons 8-14 for direct sequencing
of the amplicons, whereas for one specimen, the product was subcloned (pCRII-TOPO)
and multiple plasmid clones were sequenced. For 2 samples, exons 11, 12 and 14 were
individually amplified and sequenced from genomic DNAs.

FBW7 mutations were

detected in exon 11 for 5 patients (11%, Table 8), all of which were heterozygous and
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one (R465C) of which was previously documented as inactivating91-93. For one sample,
there was an additional heterozygous insertion of 49 nucleotides in exon 8 that is
predicted to result in early translation termination. As expected, all of the samples with
FBW7 mutations were accompanied by wild-type PEST sequence for NOTCH1. Thus,
when combined with the 7 T-ALL specimens with PEST domain mutations, 12 of 47
(25%) samples exhibited disruptions of FBW7 function. Two of the samples with FBW7
mutations contained wild-type NOTCH1, whereas the other three of the FBW7 mutants
were accompanied by mutations in the HD domain of NOTCH1 (Table 8).
We found no statistically significant difference in the frequencies of NOTCH1
plus FBW7 mutations between the 23 patients who failed treatment (10 of 23) and the 24
patients who did not fail treatment (8 of 24) (p=0.5556) (Figure 5B).
2.3c PTEN Levels and Mutations in Primary T-ALL Specimens
Since NOTCH1 has been reported to directly (activate, via CSL)229 and indirectly
(repress, via HES1 and cMYC)166 regulate PTEN, we extended our analysis of our TALL cohort to include this important gene, given its likely relevance to clinical responses
to therapy. We initially performed real-time RT-PCR analysis of PTEN transcript levels
for the 47 T-ALLs. PTEN transcript levels spanned an 833-fold range. PTEN transcripts
exhibited a slight positive correlation (Spearman’s analysis) with transcript levels of both
HES1 (r=0.3507; p=0.0157) and cMYC (r=0.3840; p=0.0077).
For 43 samples for which there was sufficient RNA, the entire PTEN coding
region was amplified using primers in the 5’ and 3’ UTRs for direct sequencing with
gene-specific primers.

With a few samples, amplicons were subcloned into a T/A

cloning vector and individual plasmid clones were sequenced. Altogether, PTEN
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Table 8: Summary of FBW7 Mutations in the 47 Pediatric T-ALL Specimens
Sample
1
2
12
17
18

DNA Changes

Amino Acid Changes

NOTCH1 Status

INS1011 (49nt); G1543T

Stop@322; R465L

INS1609(PQP); A1610T

C1542T

R465C

R1633L

C1662A

R505S

DEL 1676(V)

G1543T

R465L

WT

C1542T

R465C

WT

The position of FBW7 mutations is based upon the database sequences for FBW7 (NM_033632.2 [isoform
1], NM_018315.4 [isoform 2], NM_001013415.1 [isoform 3]). Abbreviations are: INS, Insertion; DEL,
Deletion; DUP, Duplication; *, Stop codon; nt, Nucleotide; N/A, Not Available; UTR, Untranslated
Region; WT, Wild type; ∆, changed sequence.
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mutations were detected in 25 of 43 specimens, 22 of which would result in truncated
proteins (Table 9). Eight of the 25 mutations were homozygous. The higher frequency
of both heterozygous and homozygous PTEN mutations in our T-ALL cohort are
different from results previously reported166,

181

, but this may reflect inclusion of

approximately 50% of patients who relapsed within 4 years in our study. Regardless of
the NOTCH1 and FBW7 mutational status, the loss of PTEN in these samples should
result in increased AKT signaling and resistance to standard chemotherapy and GSIs166.
However, constitutively high AKT signaling may also occur independent of PTEN
mutations due to inactivating posttranslational modifications of the PTEN protein198,
however, this has not been independently confirmed.

Further, NOTCH1 may also

activate mTOR independent of the PTEN/PI3K/AKT axis181.
For the 43 patients whose PTEN status was established, we found no significant
difference in the frequencies of PTEN mutations between the 22 patients who failed
treatment (15 of 22 PTEN mutants) and 21 patients who did not fail treatment (12 of 21
PTEN mutants) (p=0.5365). With the 43 patients for whom all three genes (PTEN,
NOTCH1 and FBW7) were analyzed for mutations, there was no significant difference
between the number of children who failed treatment and had any combination of PTEN,
NOTCH1 and FBW7 mutations (16 of 22) and those who harbored these mutations and
did not relapse (14 of 21 patients) (p=0.7470) (Figure 6).
2.3d Activating Potential of Patient-Derived NOTCH1 Mutations
To consider the possibility that the different NOTCH1 mutations identified in 16
primary T-ALL patient specimens may exhibit different activating potentials, we
prepared mutant NOTCH1 constructs containing these HD and PEST domain mutations.
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Table 9: Summary of PTEN Mutations in the 47 Pediatric T-ALL Specimens
Sample
1
2
3
4
5
6

21
22

DNA Changes
N/A
G115T
G509C; C541A
N/A
INS209 (52nt)
A80G; INS83 (67nt); DEL 84-487; G492T
C733T; G735C; C737A; G738A; A741C;
INS743 (CA); INS745 (TTTCT)
DEL697 (C)
WT
DEL 165-209; T750G; G752A;T253G;
G754A; T756A; A757T
DEL 245-1212; INS 34nt from 3'UTR
WT
N/A
INS209 (52nt)
N/A
N/A
WT
WT
A80G; DEL84-208; INS83 (71nt)
INS211 (39nt) after 211
G877C; A878G; A879G; T881G; DEL 883900
DEL 164-1026
G29T; INS492 (156nt)

23

G698T; A699T; C700A; INS702 (AG)

24
25
26
27

G738A; INS738 (GAGCCCCT)
INS736 (GG); C737G; T882C; G949A
G566C; C737A; INS737 (GAATAGGGA)
DEL 262-979
INS79 (186nt); DEL80-209; INS209 (52nt);
DEL635-1026
A80G; DEL84-164; INS83 (68nt);
DEL 165-487; G492T

7
8
9
10
11
12
13
14
15
16
17
18
19
20

28
29
30

DEL493-634

31

G698A; INS698 (GGTAT); INS753 (GC)

32

C697G; INS697(A)

33

DEL493-634

34

INS645 (ACCCTTTT); G766C

Amino Acid Changes
N/A
G39F
S170T; L181M
N/A
C71W; A72G; E73I; R74*
∆27-46(CIHFCGCSSLPFCHSLRTWE): N48*
Q245Y; P246Q; L247F; V249M; C250F; G251L; D252V;
I253W; K254*
∆233-253 (EEKTSSCTLSSLSRYLCVVIS); V255*
WT
R55S; DEL 56-70 (FLDSKHKNHYKIYNL); C250W;
G251E; D252K; I253F
N82R; C83*
WT
N/A
C71W; A72G; E73I; R74*
N/A
N/A
WT
WT
Y27C; ∆30-41 (FCGCSSLPFCHS) 43-46 (RTWE); R47*
INS 71 (SWSYQGTANHTDI); G306A; S307G; L308R;
A309*
F56*
S10I; ∆165-170 (ILQEVF) 172-177 (IKALLS); Y178*
R233L; ∆235-249 (RKTSSCTLSSLSRYL) 251-252 (VV)
254-255(SK); E256*
L247E; ∆249-257 (LYLCVVISK); F258*
∆246-249 (TGYL) 251-252 (VV) 254-255 (SK); E256*
R189T; P246Q; INS 246 (NRE)
DEL 88-327
∆27-32 (LYLTRH); I33*
Y27C; ∆29-41 (HFCGCSSLPFCAS) 43-46 (RTWE); R47*
G165I; V166L; T167S; I168L; P169W; Q171A; R172S;
R173*
∆143-228
(QVYGKTSSCTLSSLSRYLCVVRYQSRVLPQTEQDAK)
230-239 (GQNVSLLGKY) 241-248
(LHTRTRGNLRKSRKWKSM); V249*
∆293-201 (ETGRQVHVL); T202*
G165I; V166L; T167S; I168L; P169W; Q171A; R172S;
R173*
∆216-222 (TLLWSAS); K223*

The position of PTEN mutations is based upon the database sequences for PTEN (NM_000314.4).
Abbreviations are: INS, Insertion; DEL, Deletion; DUP, Duplication; *, Stop codon; nt, Nucleotide; N/A,
Not Available; UTR, Untranslated Region; WT, Wild type; ∆, changed sequence.
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Figure 6: The Prognostic Value of PTEN Mutations in Combination with NOTCH1
and/or FBW7 Mutations
20

Patient Number

16/22
14/21

No Mutations
Any Mutations
P= 0.7470

10

7/21

6/22

0
Failed

Not Failed

Treatment Outcome
The association between the presence of at least one mutation in NOTCH1, FBW7, or PTEN, or a
combination of all three genes, with treatment outcome was tested using Fisher’s Exact test. There was no
difference in the frequency of mutations (single gene or combination of all 3) between those patients who
failed treatment (16 of 22 patients harbored mutations) and those who did not fail treatment (14 of 21
patients harbored mutations; p=0.7470). Patients who failed treatment relapsed with in 4 years of
treatment. Patients who did not fail treatment were in remission at least 4 years following treatment.

.
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Mutant NOTCH1 constructs in pcDNA3 were transiently transfected into U20S cells
with a HES1-Luc reporter construct; firefly luciferase activities (normalized to Renilla
luciferase) were compared to those for wild-type NOTCH1 and ICN1. The 16 clinically
relevant NOTCH1 mutants showed increased transactivating potentials toward HES1-Luc
over wild-type NOTCH1 (1.3-3.3-fold), albeit consistently less than by ICN1 (Figure
7A). Interestingly, most NOTCH1 constructs with mutations in either the PEST domain
alone, or in combination with HD domain mutations, showed higher levels of reporter
gene activation than constructs with mutations in the HD domain alone. This result is
somewhat different from that reported by Weng et al.125 based on a much smaller group
of clinically relevant NOTCH1 mutants.
2.3e Analysis of Downstream Gene Targets of NOTCH1 as a Measure of
Downstream Signaling

To evaluate overall NOTCH1 signaling resulting from mutations in NOTCH1 and
FBW7 genes as measures of possible ‘gain-of-function’ or constitutive activity, real-time
PCR was used to measure transcript levels for HES1, DTX1 and cMYC, all documented
NOTCH 1 gene targets105-108, in the 47 T-ALL specimens. Transcript levels for cMYC
and DTX1 significantly correlated with HES1 transcripts [Spearman’s correlation
coefficient r=0.5219 (cMYC) and 0.6829 (DTX1); p=0.0002 and p<0.0001, respectively]
over a 38-300-fold range of expression. Median transcript levels for HES1, DTX1 and
cMYC were all increased in the NOTCH1/FBW7 mutant group over specimens
expressing wild-type NOTCH1/FBW7 (5.6-, 4.0-and 1.9-fold, respectively); however,
transcript levels were remarkably variable and appreciably overlapped between the
groups. For HES1 and cMYC, differences between the mutant and wild-type groups
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Figure 7: Potencies of Clinically Relevant NOTCH1 and FBW7 Mutations as
Measured by Reporter Gene Assays
A:

B:

Human U20S cells were transiently co-transfected in 35mm dishes with 0.9 µg of the indicated NOTCH1
expression plasmid alone (A), or with 0.9 µg of both a NOTCH1 expression plasmid and FBW7 expression
plasmid (B). For (A), 1 µg of HES1-Luc reporter gene construct and 30 ng of Renilla luciferase (pRLSV40) internal control were used, whereas for (B), 500 ng HES1-Luc and 30 ng of pRL-SV40 were used.
For all transfections, constant plasmid was maintained a 0.9 µg of pcDNA3 plasmid per well. Results
represent normalized luciferase activities of whole cell lysates, relative to a control in which HES1-Luc
was co-transfected with 0.9 µg pcDNA3 vector in lieu of NOTCH1/FBW7 (assigned a value of 1). Results
were presented as mean values ± standard errors [n=6 for (A); n=6 for (B)]. For (A), p-values were
calculated using paired t-tests, comparing the luciferase activities of the different NOTCH1 mutations to
wild-type NOTCH1 (*, p≤0.05: **, p≤0.005). For (B), p-values were calculated using paired t-tests,
comparing the clinically relevant NOTCH1 and FBW7 mutants as shown in the figure. For (A), the sample
numbers designate the patient samples listed in Table 3. For (B), NOTCH1 and FBW7 forms refer to the
sample numbers in Table 4. For sample 1, (a) is the early termination at position 322 and (b) is R465L.
Abbreviations are: WT, wild-type; ∆, ICN; NA, no addition.
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Relative Gene Expression

Figure 8: Expression of HES1, DTX1 and cMYC Transcripts in Patients Harboring
NOTCH1 and/or FBW7 Mutations
p=0.0820

100

10

p=0.0102

p=0.0147

1
Wild Type NOTCH1/FBW7
Mutant NOTCH1/FBW7

0.1

0.01
HES1

DTX1

cMYC

NOTCH1 Target Genes
Transcript levels were measured using real-time RT-PCR and normalized to those for GAPDH. Results are
shown for HES1, DTX1 and cMYC transcript levels in T-ALL specimens exhibiting NOTCH1 and/or
FBW7 mutations and T-ALL specimens characterized by wild-type NOTCH1 and FBW7. Data were
analyzed using the nonparametric Wilcoxon test. Horizontal bars represent median values.
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were statistically significant (p=0.0147 and 0.0102 respectively) (Figure 8).
For the 13 specimens with only NOTCH1 mutations, we showed similarly
increased levels of HES1 (5.8-fold; p=0.0817), DTX1 (3.2-fold, p=0.2010), and cMYC
(2.7-fold; p=0.0083) over the 29 specimens without either NOTCH1 or FBW7 mutations.
In contrast to our results for the HES1-luciferase reporter assays (Figure 7A), for samples
identified as harboring NOTCH1 mutations, there was no difference in the patterns of
expression for downstream target genes between samples with HD mutations alone,
versus those with PEST mutations alone, or between samples with only one mutant
domain versus those with mutations in both the HD and PEST domain. Further, for
individual NOTCH1 mutations, there was no consistent association between reporter
activities and overall NOTCH1 signaling (as reflected in HES1/DTX1/cMYC
transcripts). These results likely reflect contributions from other factors such as FBW7 in
determining levels of overall NOTCH1 signaling, as noted above.
Since three of the samples with FBW7 mutations also contained NOTCH1 HD
mutations (Table 8), it was possible to separate the impact of FBW7 mutations from that
resulting from NOTCH1 mutations on overall signaling for only a very small number of
samples.

For the 5 samples with FBW7 mutations (with and without NOTCH1

mutations), the transcript levels of HES1 and DTX1 were increased (4.6- and 4.0-fold
respectively) over samples with wild-type FBW7. However, these differences were not
significant.
The impact of the clinically relevant FBW7 mutations on transactivation of a
HES1 reporter (HES1-Luc) on top of that resulting from the clinically relevant NOTCH1
mutations (in samples 1, 2, 12; Tables 7 and 8) or wild-type NOTCH1 (for samples 17
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and 18) was further analyzed by reporter gene experiments (Figure 7b). Mutant FBW7
constructs in pcDNA3 were transiently transfected into U20S cells with the HES1-Luc
reporter, together with wild-type or mutant NOTCH1 constructs, as appropriate.
Whereas wild-type FBW7 had minimal impact on HES1 transactivation with wild-type
NOTCH1, when tested in their clinically relevant contexts (Table 8), the FBW7 mutants
augmented transactivation by both wild-type and mutant NOTCH1 (1.4- to 1.6-fold). For
FBW7 mutants 2 and 12, these increases were statistically significant (p=0.0359 and
p=0.0443, respectively).
Thus, although levels of HES1/DTX1/cMYC transcript in T-ALLs might be
expected to be the most accurate measures of overall NOTCH1 signaling and reflect the
impact of both NOTCH1 and FBW7 mutations along with other factors (e.g., NUMB),
we found no significant difference in the distribution of HES1/DTX1/cMYC transcript
levels (i.e., greater or less than the median value) between the group of patients who
failed therapy and patients who did not [p=0.7683 (HES1), 0.559 (DTX1), and 0.7683
(cMYC)].
2.3f Expression Analysis of Chemotherapy-Related Genes in Primary T-ALLs and
Relationship to NOTCH1 Signaling

We hypothesized that differences in prognostic value of NOTCH1 and FBW7
between studies91, 125, 131, 132, 135, 138, 140 (including our own) may reflect the inclusion of TALL specimens from patients treated with different chemotherapy protocols and the
possibility that aberrant NOTCH1 signaling may impact sensitivities to various
chemotherapy drugs to different extents. We used real-time RT-PCR with our 47 patient
T-ALL cohort to measure transcript levels for 22 gene targets most relevant to major
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drugs used to treat T-ALL, including asparaginase, doxorubicin, 6-mercaptopurine,
methotrexate, corticosteroids and vincristine.

Genes of interest encoded drug

transporters, drug metabolizing enzymes, drug targets or apoptosis signaling proteins that
included (a) ABCG2, (b) ABCC1, (c) ABCC2, (d) ABCC3, (e) ABCC4, (f) ABCC5, (g)
asparagine

synthetase,

(h)

B-cell

leukemia/lymphoma

2

(BCL2),

(i)

B-cell

leukemia/lymphoma X long isoform (BCL-XL), (j) dihydrofolate reductase, (k)
folypolglutamate synthetase, (l) γ glutamyl hydrolase, (m) glucocorticoid receptor, (n)
human reduce folate carrier, (o) hypoxanthine guanine phosphoribosyl transferase, (p)
MDR1, (q) microtubule-associated protein 4, (r) thiopurine methyltransferase, (s)
topisomerase 2α, (t) topoisomerase 2β, (u) β tubulin class 1, and (v) β tubulin class 3.
For each of these genes, a broad range of transcript levels was detected, from
slightly over 569-fold for AGCG2 to 6.7-fold for BCL-XL. When transcript levels for
the individual genes were correlated with relative NOTCH1 signaling, as reflected in
HES1, DTX1 and cMYC transcript levels, elevated transcript for these established
NOTCH1 gene targets were accompanied by consistent and statistically significant
increases (1.5-3.0 fold) in transcript levels for MDR1, ABCC5, asparagine synthetase,
Bcl-2, human reduced folate carrier, dihydrofolate reductase, and thiopurine
methyltransferase (Figure 9; Tables 10-12).

Folylpolyglutamate synthetase and

hypoxanthine phosphoribosyltransferase were associated with elevated expression for 2
or the 3 established NOTCH1 targets (HES1 and DTX1, and HES1 and cMYC,
respectively). For the entire cohort of 47 T-ALL patients, transcript levels for none of
these 22 genes were prognostic, in contrast to our previous findings in BP-ALL228.
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Figure 9: Expression of Relevant Chemotherapy Genes in Relation to HES1
Expression

Patients with HES1 transcript levels below the median value were considered to have low HES1
expression, and those with HES1 transcript expression above HES1 median values were considered to have
high HES1 expression. Relative transcript levels for 22 chemotherapy-related genes were measured by
real-time RT-PCR. Horizontal bars represent median values. Twelve of 22 genes were significantly overexpressed in samples with high HES1 transcripts (p<0.05 by non-parametric Wilcoxon test) and of these,
the 7 gene targets in the figure also showed a statistically significant association with levels of DELTEX1
and cMYC transcripts. Abbreviations: ABCC5, Multidrug resistance-associated protein 5 (MRP5); ASNS,
asparagine synthetase; BCL2, B-cell leukemia/lymphoma 2; DHFR, dihydrofolate reductase; hRFC, human
reduced folate carrier; MDR1, multidrug resistance 1; TPMT, thiopurine-S-methyltransferase
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Table 10: Expression of NOTCH1 Target Genes and Chemotherapy Relevant Genes
in Both Low and High HES1 Expression Patients
TRANSCRIPTS (RELATIVE UNITS)
SYMBOL Low HES1 Expression (n=23) High HES1 Expression (n=24)
P
Range
Median
Range
Median
ABCC1
16.09-199.8
46.08
14.64-272.0
48.00
0.9915
ABCC2
0.6033-77.90
5.877
1.718-54.40
9.019
0.3437
ABCC3
0.2319-12.40
2.619
0.3660-42.78
4.672
0.0235
ABCC4
5.061-37.22
15.14
4.159-95.96
24.02
0.0124
ABCC5
11.70-127.8
36.86
14.92-286.0
71.95
0.0007
ABCG2
0.3620-6.856
1.580
0.06943-39.50
1.069
0.2293
ASNS
1.794-20.40
4.829
4.466-45.83
10.68
<0.0001
BCL2
12.55-87.73
29.75
14.10-240.5
71.72
<0.0001
BCL-XL
14.15-78.15
28.53
11.63-76.31
30.18
0.6473
DHFR
13.99-86.02
28.70
16.14-143.2
60.78
0.0002
FPGS
7.993-43.58
17.00
12.57-63.21
25.37
0.0117
GCR
24.57-368.8
63.53
38.67-665.2
133.7
0.0026
GGH
0.1907-6.639
1.878
0.2334-14.57
1.604
0.8565
HPRT
6.223-25.00
12.22
5.946-54.13
18.30
0.0037
hRFC
3.485-294.4
11.50
7.127-779.8
27.11
0.0117
MAP4
7.153-49.64
14.16
1.686-70.70
16.05
0.6627
MDR1
24.40-577.1
118.9
39.56-1301
230.2
0.0009
TPMT
3.612-46.23
8.528
6.630-213.8
25.58
<0.0001
TOP2A
1.007-19.13
4.463
0.1085-26.64
7.014
0.9915
TOP2B
8.263-129.0
22.82
5.078-86.55
34.42
0.1036
TUBB1
204.1-912.5
330.1
105.2-1320
375.9
0.8232
TUBB3
0.08313-2.510
0.2958
0.08392-1.295
0.3261
0.8232
n=number of patients studied. Patients with HES1 transcript expression below the median value were
considered to have low HES1 expression, and those with HES1 transcript expression above HES1 median
values were considered to have high HES1 expression. Relative transcript levels for the target genes were
measured by real-time RT-PCR as described in Materials and Methods. Gene abbreviations are summarized
in the legend to Table 4. The non-parametric Wilcoxon test was used for comparisons of transcript levels
between groups and the p values are reported in the table. Bold and italicized entries were statistically
significant between the groups.
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Table 11: Expression of NOTCH1 Target Genes and Chemotherapy Relevant Genes
in Both Low and High DELTEX1 Expression Patients
TRANSCRIPTS (RELATIVE UNITS)
SYMBOL Low DTX1 Expression (n=23) High DTX1 Expression (n=24)
P
Range
Median
Range
Median
ABCC1
14.64- 101.8
42.80
19.15- 272.0
48.34
0.2211
ABCC2
0.6033- 37.03
3.910
1.718- 77.90
10.10
0.0325
ABCC3
0.2319- 42.78
3.385
0.3660- 25.09
4.582
0.4006
ABCC4
9.428- 95.96
16.79
4.159- 59.19
25.90
0.1509
ABCC5
11.70- 121.2
38.89
24.00- 286.0
70.75
0.0059
ABCG2
0.1010- 6.856
1.598
0.06943- 39.50
1.069
0.4126
ASNS
1.794- 40.37
4.829
4.466- 45.83
10.67
0.0007
BCL2
12.55- 215.1
29.75
18.82- 240.5
66.37
<0.0001
BCL-XL
11.63- 78.15
28.39
14.04- 76.31
35.29
0.3021
DHFR
14.78- 143.2
33.13
13.99- 128.8
57.83
0.0132
FPGS
7.993- 41.81
17.78
13.36- 63.21
25.08
0.0042
GCR
24.57- 336.5
58.69
58.50- 665.2
133.7
0.0003
GGH
0.2483- 6.305
1.792
0.1907- 14.57
1.806
0.9406
HPRT
6.223- 31.62
12.87
5.946- 54.13
17.41
0.0722
hRFC
3.485- 429.8
14.23
7.088- 779.8
27.68
0.0277
MAP4
4.404- 49.64
11.49
1.686- 70.70
18.23
0.0081
MDR1
24.40- 1301
131.0
40.43- 729.9
225.5
0.0149
TPMT
3.612- 213.8
9.779
5.546- 131.4
19.31
0.0034
TOP2A
0.7263- 22.05
5.242
0.1085- 26.64
4.432
0.6321
TOP2B
7.936- 129.0
22.89
5.078- 87.59
29.50
0.1129
TUBB1
134.3- 759.6
391.3
105.2- 1320
346.5
0.9068
TUBB3
0.08313- 1.513
0.2262
0.08392- 2.510
0.3261
0.4892
n=number of patients studied. Patients with DELTEX1 transcript expression below the median value
were considered to have low DELTEX1 expression, and those with DELTEX1 transcript expression above
DELTEX1 median values were considered to have high DELTEX1 expression. Relative transcript levels
for the target genes were measured by real-time RT-PCR, as described in Materials and Methods. Gene
abbreviations are summarized in the legend to Table 4. The non-parametric Wilcoxon test was used for
comparisons of transcript levels between groups and the p values are reported in the table. Bold and
italicized entries were statistically significant between the groups.
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Table 12: Expression of NOTCH1 Target Genes and Chemotherapy Relevant Genes
in Both Low and High cMYC Expression Patients
TRANSCRIPTS (RELATIVE UNITS)
P
SYMBOL Low cMYC Expression (n=24) High cMYC Expression (n=23)
Range
Median
Range
Median
ABCC1
16.09- 199.8
49.89
14.64- 272.0
43.30
0.3021
ABCC2
0.6033- 48.27
6.053
1.060- 77.90
8.680
0.6021
ABCC3
0.2319- 8.135
2.404
0.3660- 42.78
5.142
0.0034
ABCC4
5.061- 42.09
14.61
4.159- 95.96
29.81
<0.0001
ABCC5
11.70- 111.4
36.03
31.10- 286.0
68.57
0.0002
ABCG2
0.4111- 6.856
1.563
0.06943- 39.50
1.249
0.2549
ASNS
1.794- 17.13
5.540
4.466- 45.83
10.48
0.0020
BCL2
12.55- 94.73
30.26
13.29- 240.5
68.92
0.0001
BCL-XL
14.04- 78.15
27.15
11.63- 76.31
31.46
0.4892
DHFR
13.99- 83.52
28.13
23.56- 143.2
63.01
<0.0001
FPGS
7.993- 44.48
17.65
8.093- 63.21
20.11
0.1082
GCR
32.49- 212.2
70.28
24.57- 665.2
130.6
0.0597
GGH
0.2334- 6.720
2.225
0.1907- 14.57
1.591
0.5027
HPRT
6.223- 42.61
12.34
5.946- 54.13
18.04
0.0308
hRFC
3.485- 294.4
11.37
7.127- 779.8
26.62
0.0097
MAP4
7.153- 70.70
14.42
1.686- 59.68
15.03
0.9915
MDR1
24.40- 424.2
128.2
40.43- 1301
230.8
0.0017
TPMT
3.612- 36.73
10.73
5.791- 213.8
26.57
0.0008
TOP2A
0.9799- 19.75
4.751
0.1085- 26.64
5.242
0.9406
TOP2B
8.263- 129.0
23.02
5.078- 87.59
30.66
0.1036
TUBB1
198.9- 1320
359.6
105.2- 912.5
362.8
0.9745
TUBB3
0.08313- 1.513
0.2646
0.08392- 2.510
0.3405
0.5874
n=number of patients studied. Patients with cMYC transcript expression below the median value were
considered to have low cMYC expression, and those with cMYC transcript expression above cMYC
median values were considered to have high cMYC expression. Relative transcript levels for the target
genes were measured by real-time RT-PCR, as described in Materials and Methods. Gene abbreviations
are summarized in the legend to Table 4. The non-parametric Wilcoxon test was used for comparisons of
transcript levels between groups and the p values are reported in the table. Bold and italicized entries
were statistically significant between the groups.
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2.3g Identification of NOTCH1, FBW7 and PTEN Mutations at Diagnosis and
Relapse

To begin to investigate potential genetic alterations that contribute to relapse in TALL, we assessed the frequencies of mutations in NOTCH1 alone, and in combination,
with mutations in FBW7 and PTEN at the time of diagnosis and relapse in paired clinical
T-ALL specimens. The immediate goal was to evaluate the stability of alterations in
these three genes and to determine if any genetic alterations were associated with disease
progression and treatment failure. It is reasonable to hypothesize that these mutations
may be causal factors in relapsed T-ALL since we have shown that aberrant NOTCH1
signaling is associated with the increased expression of chemotherapy drug
resistance/sensitivity genes (above), and we and others have shown that PTEN is
frequently inactivated, either by mutations or post-translational modifications, which can
lead to increased Akt activity and chemotherapy resistance198.
For this study, we analyzed paired diagnostic and relapsed samples from 11 TALL patients. The patient characteristics are summarized in Table 13. The cohort
included eight males with a median diagnostic age of 120 months (10 years) and three
females with a median diagnostic age of 161 months (13.4 years). The overall time to
relapse (from the date of the initial diagnosis) was 10 months, with the males exhibiting a
slightly faster relapse time of 9.5 months.
2.3g i Identification of NOTCH1 and FBW7 Mutations
NOTCH1, FBW7 and PTEN mutations were amplified and identified in the
RNAs or gDNAs isolated from cryopreserved lymphoblasts or DNAs isolated from bone
marrow aspirate slides. The mutational status of this paired cohort is summarized in
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Table 13: Characteristics of the 11 Paired Pediatric T-ALL Specimens
Sample
Age at
Time to
Sex
Race
WBC/µl
ID
Diagnosis
Relapse
F
n/a
n/a
84m (7y)
11m
T20184
M
n/a
187,000
120m (10y)
4m
T20319
M
W
n/a
72m (6y)
29m (2y5m)
T20320
M
W
n/a
163m (13y7m)
17m (1y5m)
T20321
F
A
29,337
161m (13y5m)
10m
T20322
M
n/a
160,000
48m
(4y)
6m
T20323
M
A
160,000
180m (15y)
3m
T20324
M
n/a
n/a
69m (5y9m)
14m (1y2m)
T20326
M
A
n/a
156m (13y)
5m
T20327
M
H
107,000
120m (10y)
13m (1y1m)
T20328
F
W
n/a
180m (15y)
5m
T20329
The overall median age at the time of diagnosis was 120 months (10 years) with a standard
deviation of 48.28 months. The median time to progression was 10 months with a standard
deviation of 7.632 months. For the 8 males, the median age at diagnosis was 120 months
(10 years), while the female had a median age of 161 months (13.4 years). The males had a
median time to relapse of 9.5 months, slightly shorter than the female median age to relapse
of 10 months. Abbreviations: F, female; M, male; W, White; A, African American; H,
Hispanic; n/a, not available; WBC, white blood cell; m, months; y, years.

76

Table 14. Surprisingly, all eleven patients had wild-type FBW7 at both diagnosis and
relapse. Seven patients exhibited wild-type NOTCH1 at both diagnosis and relapse. For
these patients, the median age at diagnosis was 156 months (13 years) with a median time
to relapse of 6 months. Three of these patients with wild-type NOTCH1 (T20184,
T20324 and T20327) had single nucleotide polymorphisms (C5094T or G7083A) that did
not change the NOTCH1 amino acid sequence. The exception is patient T20327, who at
relapse acquired a SNP in NOTCH1. These data suggest that for this group of patients,
mutant NOTCH1 does not appear to be a casual factor of relapse.
Four patients harbored NOTCH1 mutations at diagnosis, relapse, or both.
Together, these four mutant NOTCH1 patients had a median diagnostic age of 120
months (10 years) with a median time to progression of 11.5 months. Two patients
(T20320 and TT20322) had NOTCH1 mutations at both diagnosis and relapse, but the
mutation at relapse differed from that at diagnosis. Interestingly, these patients relapsed
29 months and 10 months later. One patient (T20319) had wild-type NOTCH1 at the
time of diagnosis, but acquired a NOTCH1 mutation at relapse, and experienced relapse
within 4 months. The last patient (T20328) harbored the same NOTCH1 mutation at
both diagnosis and relapse. This patient relapsed 13 months after initial diagnosis. It can
be concluded that for this cohort, patients that were wild-type for NOTCH1 were
diagnosed with T-ALL at a later age (13 years vs. 10 years), but generally experienced
more rapid rate of relapse (6 months vs. 11.5 months), however these differences were
not statistically significant.
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2.3g ii Identification of PTEN Mutations at Diagnosis and Relapse
Six patients were wild-type for PTEN at both diagnosis and relapse (Table 14),
suggesting that relapse was not caused by genetic alterations to PTEN. These patients
had a median diagnostic age of 120 months (10 y) and a median time to relapse of 5.5
months. The remaining 5 patients harbored PTEN mutations at diagnosis, relapse or
both. These patients had a median diagnostic age of 156 months (13 y) and a median
time to relapse of 14 months. Two patients (T20320 and T20327) had detectable PTEN
mutations at the time of diagnosis that completely disappeared by relapse. The time to
progression to relapse for these two individuals was 29 months and 5 months,
respectively. Two patients (T20322 and T20326) had the same PTEN mutation at the
time of diagnosis and relapse. The time to relapse progression was 10 months and 14
months, respectively. Only one patient (T20321) had different PTEN mutations at both
diagnosis and relapse, and experienced relapse 17 months after diagnosis.
2.3g iii The Impact of the Combination of NOTCH1 and PTEN Mutations at
Diagnosis and Relapse
Of the 11 patients, only 4 (36%) were completely wild-type for both NOTCH1
and PTEN. These 4 patients (T20184, T20323, T20324 and T20329) had a median age at
diagnosis of 132 months (11 y) with a median time to progression of 5.5 months. From
these 4 patients, neither NOTCH1 activation (via presence of NOTCH1 mutations) nor
PTEN inactivation (via presence of PTEN mutations) appeared to play an appreciable
role in relapse. The remaining 7 patients showed either NOTCH1 mutations, PTEN
mutations or both either at diagnosis, relapse or both. These patients had a median age at
diagnosis of 120 months (10 y) and a median time to progression of 13 months.
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Table 14: Mutational Status of the 11 Paired Diagnosis/Relapse Patients

Patient

T20184
T20323
T20324
T20329

Diagnosis
or
Relapse
D
R
D
R
D
R
D
R
D

T20326

R

T20328

D
R
D

T20321

R

DNA
Mutations
C5094T
C5094T
WT
WT
C5094T
C5094T
WT
WT

AA
Change
WT
WT
WT
WT
WT
WT
WT
WT

WT

WT

WT

WT

T4754T/C
T4754C

L1585P
L1585P

WT

WT

WT

WT

PTEN
DNA
Mutations
WT
WT
WT
WT
WT
WT
WT
WT
INS1732(ACCG),
INS1768(CT),
G1769A
INS1732(ACCG),
INS1768(CT),
G1769A
WT
WT
INS1730(A)
Del 1348-2473

AA
Change
WT
WT
WT
WT
WT
WT
WT
WT
∆235-243

∆235-243
WT
WT
∆234-241,
stop@242
∆106-119,
∆121-125,
stop@126
P246R
WT
Y27C
WT
WT

A4808A/G N1603S
C1768C/G
G4948A
A1650T
WT
WT
WT
A1111G
T20327
G7083G/A
WT
WT
C5094C/T
WT
WT
T5039T/A,
T20319
R
C5094C/T I1680N
WT
WT
C5094C/T,
stop@
T1913T/G
S294R
D
C7470C/A
2490
T20322
C5094C/T,
I1718T
T1913T/G
S294R
R
T5153T/C
The position of NOTCH1 mutations is based upon the database sequences for NOTCH1 (NM_017617.3).
The position of PTEN mutations is based upon the database sequences for PTEN (NM_000314.4).
Abbreviations are: INS, Insertion; DEL, Deletion; WT, Wild type; ∆, changed sequence.
T20320

D
R
D
R
D

NOTCH1
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Based on these data in this small cohort of paired specimens, the presence of NOTCH1
and/or PTEN mutations may indeed be associated with a delay in relapse. However, it
does not appear that relapse is associated with the presence of these mutations, and that
some other underlying factor is most likely causal.
2.3g iv Activating Potential of NOTCH1 Mutations in Diagnostic and Relapse
Samples
The transactivating potential of the NOTCH1 mutations was assessed by
determining the impact of these mutations on the transactivation of a HES1-Luc reporter
(Figure 10). As described above, for these experiments, mutant NOTCH1 constructs in
pcDNA3 were transiently transfected into U20S cells with the HES1-Luc reporter. As
was seen with the 16 NOTCH1 mutations in the 47 T-ALL cohort, these mutations were
activating to different degrees, ranging from 1.5 to 2.6-fold increases in the HES1-Luc
reporter activity. Interestingly, only the NOTCH1 mutation in T20319R induced a
statistically significant increase in activity compared to wild-type NOTCH1 (p=0.0492).
2.3g v Detection of Relapse Clones at Diagnosis
For 5 patients (T20319, T20320, T20321, T20322 and T20327), there is the
emergence of a new mutation, either in NOTCH1 and/or PTEN, at the time of relapse, or
in the case of T20327R, the loss of a mutation (Table 14). From these data, we can only
assume that relapse must have arisen from a new leukemic clone. However, whether this
clone is identical to the diagnostic clone, but acquired a new genetic mutation, or if it is a
completely different clone that was present as a minor subpopulation at diagnosis is
unknown. We made these assumptions based upon the fact that different NOTCH1 and
PTEN mutations were detected at the time of diagnosis and relapse (Table 14). We
hypothesized that these relapse leukemic clones were already present at the time of
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Figure 10: Activity of NOTCH1 Mutations in the Diagnostic/Relapse Patients

Human U2OS cells were transiently co-transfected in 35 mm dishes with 0.9 µg of the indicated NOTCH1
expression plasmid. 1 µg of HES1-Luc reporter gene construct and 30 ng of Renilla luciferase (pRL-SV40)
internal control were used. For all transfections, constant plasmid was maintained at 0.9 µg of pcDNA3
plasmid per well. Results represent normalized luciferase activities of whole cell lysates, relative to a
control in which HES1-luc was co-transfected with 0.9 µg pcDNA3 vector in lieu of NOTCH1 (assigned a
value of 1). Results are presented as mean values + standard errors. p-values were calculated using paired t
tests, comparing the luciferase activities of the different NOTCH1 mutations to wild-type NOTCH1.
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diagnosis, but were just below our limit of detection. To address this possibility, we used
real-time PCR to detect whether the newly identified relapse T-ALL clones could be
detected in the diagnostic specimens as a minor subclinical population. For this, specific
NOTCH1 hybridization probes were designed to detect the relapse NOTCH1 mutation in
patient T20319 (T5039A) and patient T20322 (T5153C) in lymphoblasts collected at
diagnosis. These methods were validated by plasmid constructs including pure wild-type
or mutant NOTCH1 sequence. For T20319, the relapse NOTCH1 mutation (T5039T/A)
was detected in the diagnostic sample at a low frequency (Figure 11), suggesting that in
this patient, the relapse leukemic clone was indeed present at diagnosis and was able to
escape chemotherapy, perhaps because this NOTCH1 mutation rendered it resistant to
chemotherapy. For T20322, the relapse NOTCH1 mutation (T5131T/C) was not detected
at diagnosis (Figure 11).

This suggests that either this leukemic clone arose after

chemotherapy or our detection method was not sufficiently sensitive to detect it at
diagnosis.
2.4 Conclusions
Our results suggest that multiple factors should be considered when attempting to
identify molecularly-based prognostic factors for pediatric T-ALL. Our results further
established the presence of high frequency mutations in NOTCH1 and FBW7 in pediatric
T-ALL.

Mutant NOTCH1 was associated with a range of activating potentials, as

reflected in activities from HES1 promoter-reporter gene assays that were consistently
elevated over wild-type NOTCH1. Although mutant NOTCH1 and mutant FBW7 were
associated with increased HES1 promoter-reporter activities and increased transcript
levels for the NOTCH1 target genes, HES1, DTX1, and cMYC, the range of transcripts
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Figure 11: Detection of Relapse T-ALL Clone as a Subclone at Diagnosis

A. T20319
Diagnostic
Relapse

B. T20322

T5153

Diagnostic
C5153

Relapse

Genotype analysis of (A) T20319 (NOTCH1 mutation T5039A) and (B) T20322 (NOTCH1 mutation
T5153C) was performed using a LightCycler real time PCR with gene-specific primers and 3’fluoresceinlabeled and 5’LC-red640-labeled hybridization probes. Samples were amplified over 35 cycles, and
melting curves for the products were analyzed at 640nm for 40°-80°C at a rate of 0.3°C/sec. For A, the
blue line is pure wild-type NOTCH1 template (TT) and the green line is the pure mutant template (AA).
Patient gDNAs are designated by the red line (Diagnostic) and the black line (Relapse). The pink line
designates the negative control. For B, the blue line designates pure wild-type NOTCH1 template (TT) and
the green line is the pure mutant template (CC). Patient gDNAs are designated by the black line
(Diagnostic) and the red line (Relapse). The teal-green line designates the negative control.
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was surprisingly broad and there was significant overlap between the mutant and wildtype T-ALL samples. This appears to reflect the different transactivating potencies for
the various NOTCH1 mutants and possibly other factors that impact overall
NOTCH1signaling [e.g., NUMB90]. Collectively, these results imply that, rather than
simply scoring the mutant status of NOTCH1 and/or FBW7, overall signaling activity, as
reflected in the cumulative transcript levels for these established NOTCH1 target genes,
is likely to be far more meaningful to the biology and therapy of T-ALL.
In our analysis, neither the presence of NOTCH1 and/or FBW7 mutations, nor
relative HES1/DTX1/cMYC transcript levels, were directly associated with treatment
failure in our pediatric cohort.

Likewise, neither PTEN mutations alone, nor

combinations of mutations in PTEN with NOTCH1 and FBW7, were prognostic.
Interestingly, elevated transcripts for the downstream NOTCH1 gene targets were
accompanied by consistent and statistically significant increases in transcript levels for
chemotherapy-related genes including MDR1, ABCC5, asparagine synthetase, Bcl-2,
human reduced folate carrier, dihydrofolate reductase and thiopurine methyltransferase.
While the nature of these associations, including causal mechanisms, is not established,
from these results, the net level of chemotherapy drug response would seem to reflect a
composite phenotype, including an increased sensitivity to methotrexate due to increased
human reduced folate carrier, and increased resistance for assorted chemotherapy agents
due to increased Bcl-2 (multiple agents), MDR1 (doxorubicin, vincristine), ABCC5 (6mercaptopurine,

methotrexate),

asparagine

dihydrofolate reductase (methotrexate).

synthetase

(L-asparaginase),

and

Perhaps most importantly, the relative

importance of these mechanisms would reflect the combinations of chemotherapy drugs
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administered, along with drug doses and schedule.

Additional determinants of

chemotherapy activity include PTEN levels or the presence of inactivating PTEN
mutations and potential downstream effects of NOTCH1 on PI3K-AKT and mTOR
signaling pathways.
Additional studies are undoubtedly necessary to establish the mechanisms (i.e.,
direct or indirect effects of NOTCH1 and downstream signaling) that result in altered
expression of these drug resistance/sensitivity genes, along with studies to extend these
results to other tumors with aberrant NOTCH1 signaling. Deregulated NOTCH signaling
involving NOTCH receptors, ligands and targets has been also observed in solid tumors
and high levels of NOTCH1 and Jagged1 ligand were associated with a poor prognosis in
breast cancer230 and metastasis in prostate cancer144. Finally, an important implication of
our results is that, depending on the NOTCH1 signaling status, modifications in the types
or dosing of standard chemotherapy drugs for T-ALL, or combinations of agents capable
of targeting NOTCH1 such as GSIs231 or AKT and mTOR inhibitors, with standard
chemotherapy agents may be warranted.
We also extended our studies of NOTCH1, PTEN and FBW7 mutations to their
potential roles in the occurrence of relapse, which is the most common cause of treatment
failure25. The 11 paired specimens were analyzed for the presence of NOTCH1, FBW7
and PTEN mutations at both diagnosis and relapse. Surprisingly, FBW7 mutations were
not detected. This implies that these mutations are not causal factors for relapse. It was
observed that the seven patients harboring mutations at some stage in their disease had a
longer remission period (13 months vs. 5.5 months), and were typically diagnosed at an
earlier age (120 months vs. 132 months). In these seven patients, nearly 70% of relapse
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appeared to be associated with the emergence of a new leukemic clone, an assumption
based on our detection of a new mutation or loss of mutation at relapse. Whether or not
these new leukemic clones were the result of an induced acquired genetic alteration or
were already present at diagnosis as a subpopulation was analyzed for 2 patients. Using
real-time PCR techniques with specific hybridization probes, the relapse clone (as
identified by the emergence of a NOTCH1 mutation) for T20319 was detected at
diagnosis, at very low levels. This establishes that this clone which may directly or
indirectly contribute to relapse was indeed present in the initial diagnostic leukemia
specimen. For patient T20322, the relapse clone (again, identified by the presence of a
different NOTCH1 mutation) was not detected at diagnosis. Assuming that our method
of detection is sufficiently sensitive to detect the clone, it appears that the relapse clone
was induced following chemotherapy. This study strongly warrants future studies with a
larger patient cohort to systematically identify specific hallmarks of relapse.
It has been documented that MRD levels are good indicators of relapse risk. In a
recent study, patients with low levels of MRD had about a 13% chance of relapsing
within 5 years, while patients with undetectable MRD following induction therapy had
only a 5% chance of relapsing232. However, such studies may be difficult to conduct
since T-ALL accounts for less than 15% of all ALL cases, and modern aggressive
therapies are increasing the cure rates for this disease.
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CHAPTER 3
THE DOWNSTREAM EFFECTS OF NOTCH1 SIGNALING:
THE DEVELOPMENT OF CELL LINE MODELS

3.1 Introduction
The discovery of ‘gain-of-function’ NOTCH1 mutations in both children and
adults with T-ALL suggests that aberrant NOTCH1 signaling is important in the
pathogenesis of T-ALL91, 125, 131, 132, 138-140. However, the exact role of NOTCH1 in the
etiology and therapy of this disease has not been well established. Inhibiting NOTCH1
signaling with γ-secretase inhibitors (GSIs) is an attractive therapeutic strategy because
NOTCH1 is mutated in such a large number of T-ALLs, and GSIs are effective at
inhibiting the NOTCH1 signaling process. Previous studies have shown that treatment of
T-ALL cell lines with GSIs can induce cell growth arrest and apoptosis125,

127, 154

.

However, Liu et al. demonstrated that GSI treatments can have different effects on
different cell lines233. Treating GSI-sensitive T-ALL cell lines TALL-1 and HSB2 with
the GSI Compound E (CompE) for 3 or 4 days resulted in G0/G1 arrest, as indicated by
accumulation of cells in G0/G1 and retention of cells in both S-phase and G2/M. GSI
treatment also induced apoptosis in these cells nearly 2.3-2.9-fold. However, in the GSIresistant cell lines, CCRF-CEM (CEM) and Jurkat, little-to-no changes were observed in
cell cycle arrest or apoptosis following GSI treatment. Pretreating TALL-1 and HSB2
cells with CompE augmented the apoptotic effect induced by treating with Lasparaginase (L-Asp) or dexamethasone. Conversely, treating CEM and Jurkat cells with
CompE prior to chemotherapeutic agents appeared to antagonize their apoptotic effect.
Thus, it appears that depending on the cell type, NOTCH1 inhibition either can induce
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apoptosis and synergize with chemotherapy, or is ineffective at inducing apoptosis and
can antagonize the chemotherapeutic effect. This is entirely consistent with the studies
described in Chapter 2.
In order to use NOTCH1 inhibition for targeted therapy, we need to fully
understand the downstream functions of NOTCH1 signaling. Only then can we begin to
apply our mechanistic insights related to NOTCH1 signaling to improved therapy for TALL. This is particularly true in the case of GSIs’ cell-specific effects. An important
goal of Chapters 3 and 4 is to better understand the downstream effects of NOTCH1
signaling, specifically the complex relationships between NOTCH1 with both the PI3KAkt and mTOR pathways, and how this maybe exploited for therapy. These pathways
are key mediators of cell proliferation and survival and are of particular interest because
there are clinically relevant inhibitors available for both pathways.

The effects of

NOTCH1 activity on these two pathways are likely to have significant impacts in
conferring chemotherapy sensitivity or resistance.

We suspect that the effect of

NOTCH1 targeting in T-ALL therapy may synergize or antagonize the activity of
standard chemotherapy agents, depending upon the characteristics of the T-ALL cell.
This chapter and the following chapter will focus on the effects of NOTCH1 signaling on
novel genes and pathways likely to impact disease progression and chemotherapy
sensitivity in clinically relevant T-ALL cell line models with differences in PTEN status
and AKT signaling.
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3.2 Materials and Methods
3.2a Cell Lines
The human T-ALL cell lines used in these studies, along with their unique
characteristics, are summarized in Table 15. The cell lines were grown in RPMI 1640,
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (100
units/mL) and streptomycin (100 µg/mL) in a humidified atmosphere at 37°C in the
presence of 5% CO2. Transient inhibition of NOTCH1 was performed using 1 µM of
Compound E ([(2S)-2-([(3,5-difluorophenyl)acetyl]amino)-N-[(3S)-1-methyl-2-oxo-5phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]propanamide]; Axxora, San Diego, CA).
Control cells were treated with an equal volume of DMSO for the same time period.
3.2b Isolation of RNA
RNAs were isolated using the TRIzol® (Invitrogen) protocol. Briefly, cells were
lysed in 1 mL TRIzol®; and phase separation was induced with 200 µL chloroform
(Fisher).

RNA was then precipitated with isopropyl alcohol (Fisher), pelleted and

washed with 75% ethanol.

The RNA pellet was allowed to air dry, followed by

resuspension in PCR-grade water. cDNAs were prepared using random hexamer primers
(see 2.2b) or oligo(dT) from SuperScriptTM III First-Strand Synthesis System for RT-PCR
(Invitrogen), and purified with the QIAquick PCR Purification kit (Qiagen).
3.2c RT2ProfilerTM PCR Array
Total RNAs were purified with the SuperArray RT2 qPCR-Grade RNA Isolation
Kit (SABiosciences; Fredrick, MD). The PI3K-AKT Signaling Pathway RT2ProfilerTM
PCR Array (SABiosciences) contained 84 genes deemed most relevant to PI3K-Akt
signaling pathway. cDNAs were prepared from 1µg RNA using RT2 First Strand Kit
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Table 15: Summary of Human T-ALL Cell Lines Used and Their Reported
Characteristics
Cell Line

NOTCH1 Status

HPB-ALL

L1575L/P;
heterozygous ins 2442
(EGRGRCSHWAPAAWRCTLFCPRRAPP
CPRRCHPRWSHP*STOP
L1594L/P; D1610D/V; heterozygous ins
2444
(CCSHWAPAAWRCTLFCPRRAPPCPRR
CHPRWSHP*STOP)
L1594L/P;
2475 (ASP*STOP)
WT
WT

R505R/C

CEM

Heterozygous ins 1595 (PRLPHNSSFHFL)

R465R/H

RPMI8402
MOLT4

Heterozygous ins 1584 (PVELMPPE)

R465H

DND-41

ALL-SIL
TALL-1

FBW7
Status

PTEN Status

GSI
Sensitivity

WT

WT

Sensitive

WT

WT

Sensitive

WT

WT

Sensitive

WT

N/A

Sensitive

2bp deletion and 9bp
insertion (exon 7) or
39bp insertion (exon 7)
Deletion exons 2-5

Resistant

Frameshift sequence at
AA236; R159S
WT

Resistant

Jurkat

Resistant

L1601L/P; heterozygous del 2515
WT
Resistant
(RVP*STOP)
Adapted from: O’Neil, J et al JEM VOL. 204, August 6, 2007; Palomero, T et al Nat Med 2007 Oct;
13(10): 1203-10; Sakai, A et al Blood, Vol 92, No 9 (November 1), 1998: pp3410-3415.
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(SABiosciences) and added to RT2 qPCR Master Mix containing SYBR Green and
reference dye. This master mix was aliquoted across the PCR plate. Thermal cycling was
performed by LightCycler 480 (Roche) and data were analyzed by software provided by
SABiosciences. Each cell line treatment was performed in duplicate, and validated by
real-time qPCR, as described in Chapter 2.
3.2d Cell Proliferation Assays
Cells were seeded at 7.5 x 104 cells/mL in a total of 10 mL of media. At 24h
intervals, cells were counted using Trypan Blue and a hemocytometer. Prism Software v.
4.0 (GraphPad) was used to graph growth and calculate population doubling times.
3.2e Western Blot Analysis
Proteins were isolated from whole cell extracts. Briefly, cells were pelleted
and dissolved in protein inhibitor (PI) mix containing 10 mM Tris, 0.5% sodium dodecyl
sulfate (SDS) and 1 tablet of Phos-STOP (Roche).

Membranes were disrupted by

sonication, cell debris was collected by centrifugation and protein-containing supernatant
was transferred to new microcentrifuge tube. Proteins were quantitated using a bovine
serum albumin (BSA) standard curve.
Proteins were electrophoresed on 10% polyacrylamide gels in the presence of
SDS and transferred to polyvinylidene difluoride membranes (Fisher). Proteins were
detected using primary antibodies of choice (see below) and a secondary IRDyeTM 800conjugated Antibody (Rockland). Detection and densitometry were performed with the
Odyssey® Imaging System (Licor; Lincoln, NE). The primary antibodies used were:
•

Cleaved Notch1 (Val1744) antibody (Cell Signaling Technology [CST];
Danvers, MA) was used in a 1:250 dilution with a tertiary detection method.
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Following

incubation

with

Val1744,

the

blot

was

washed

with

PBS+0.1%Tween, then incubated for 1hr with goat-anti-rabbit antibody in a
1:1000 dilution, followed by another wash with PBS+0.1%Tween. Lastly, the
antibody was incubated for 1hr with anti-goat 800 in a 1:1000 dilution.
•

Phospho-Akt Ser473 antibody (CST) was used in a 1:250 dilution

•

total Akt antibody (CST) was used in a 1:1000 dilution

•

4E-BP1 (CST) antibody was used in a 1:1000 dilution

•

PI3 Kinase p110α, PI3 Kinase p110γ, PI3 Kinase p110δ (CST) antibodies
were used in 1:250 dilutions

•

Phospho-S6 Ribosomal Protein (Ser235/236) (CST) antibody was used in
1:1000 dilution

•

S6 Ribosomal Protein (CST) antibody was used in 1:1000 dilution

•

PTEN (CST) antibody was used in a 1:1000 dilution

•

β-Actin (Sigma) antibody was used in 1:2000 dilution.

3.2f Lenti-viral Knockdown of NOTCH1
Jurkat cells were seeded at 2 x 105 cells/well in 1mL media in 24-well plate.
NOTCH1 shRNA particles234 and a non-targeted control (ntc, or scrambled) shRNA were
pre-packaged by Sigma (St. Louis, MO). The lentiviral particles were added to cells with
4 µg/ul polybrene and allowed to incubate for 24h at 37°C. The viral particles were
removed by centrifugation and the cells were transferred to new 24-well plate with 1mL
media and 0.25 µg/mL puromycin. The mixed transduced cultures were expanded and
plated in soft-agar to allow for the selection and isolation of single clones. Clones were
then tested for the knockdown of NOTCH1 by Western blotting and real-time qPCR.
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3.2g AnnexinV/PI/Fluorescent Bead In-Vitro Cytotoxicity Assay
The NOTCH1 knocked-down stable clones (J.ntc, J.N1KD 2-4 and J.N1KD 2-7)
in logarithmic growth phase were resuspended thoroughly and 50µl aliquots of each were
processed in triplicate using the AnnexinV-FITC/Propidium Iodide (PI) staining kit
(Immunotech; Marseille, France), according to manufacturer’s instructions.

After

incubation, samples were diluted with 400 µl of 1X AnnexinV Buffer containing
approximately 5% of FlowCount Fluorospheres (Beckman Coulter; Miami, FL) as an
internal monitor for determining relative absolute counts. Tubes were vortexed and
analyzed immediately using a Beckman Coulter XL Flow Cytometer equipped with an
Argon laser (Beckman Coulter).

Cells were gated to include the viable target cell

population based on inspection of forward scatter (FS)/ side scatter (SS) characteristics,
and absolute relative counts of AnnexinV-/PI- events (i.e.; the viable cell fraction) were
determined. Additionally, total AnnexinV+ events were recorded from the ungated cell
population to assess overall early and late apoptotic induction. All results were compared
to control tubes.
3.2h Cell Cycle Analysis
The NOTCH1 knocked-down stable clones (1 x 106 cells) were washed once in 2
mL cold PBS and resuspended in 150µl cold PBS+0.1% glucose. While vortexing, 1 mL
of cold 80% ethanol was added in a drop-wise fashion to each sample. For analysis, cells
were resuspended gently and centrifuged for 3min at 500g.

The supernatant was

removed, leaving approximately 300 µl of residual volume. The cells were again gently
vortexed and 2 mL of cold Coulter DNA-Prep reagent (Beckman Coulter) was added.
The samples were left at room temperature in the dark for 1-2h with occasional

93
vortexing, and stored overnight at 4ºC before being analyzed.

The samples were

analyzed on a Beckman Coulter XL Flow Cytometer (Beckman Coulter) by measuring PI
fluorescence on FL3 and histograms were analyzed for G0/G1, S and G2/M phase
content using defined parameters.
3.2i Cell Surface Marker Expression Analysis
The NOTCH1 knocked-down clones were resuspended in PBS+30% adult
bovine serum at a concentration of approximately 5 x 106 cells/mL and aliquoted to tubes
containing both FITC and phycoerythrin (PE)-conjugated monoclonal antibodies
(Immunotech). Cells were stained in the dark for 20 min at room temperature and
washed with 1 mL of cold PBS. The cells were then resuspended in 0.5 mL PBS+Fix
(PBS+0.4% formaldehyde). The samples were screened for two-color analysis on a
Beckman Coulter XL Flow Cytometer (Beckman Coulter) equipped with an Argon laser.
Samples were gated on the viable cell fraction as inferred from FS/SS characteristics.
Percent positivity and mean channel fluorescence rations of specific antigens were
assessed by comparisons to isotype-matched controls.
3.2j MTT Cytotoxicity Assay
Cells were resuspended in RPMI1640 containing 20% dialyzed fetal bovine
serum and 2mM L-glutamine, and seeded at 4000 cells/well in a 96-well plate.
Chemotherapeutic agents were diluted in the above medium at the highest concentration
needed, and then serially diluted until the smallest concentration needed was achieved.
The chemotherapy drug, or vehicle control, was then added to the appropriate wells. The
following chemotherapeutic agents were analyzed:


Methotrexate (MTX)
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Daunorubicin (DNR; Sigma)



VP16 (Sigma)



L-Asparginase (Sigma)

Cells were then allowed to incubate with the drug for 4 days at 37°C at 5% CO2 in a
humidified incubator.

Next, 10 µl of 2.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT; Sigma) in sterile PBS was added to cells and
incubated for 4h at 37ºC. Cells were then lysed by adding 50 µl of 10%SDS in HCl to
each well and incubated overnight at dark. Plates were read on visible microplate reader
at 595 nm.
3.3 Results
3.3a Effects of NOTCH1 Inhibition on Cell Proliferation
RPMI-8402 (mutant PTEN) and HPB-ALL (wild-type PTEN) cells were seeded
at 7.5 x 104 cells/mL and treated with 1.0 µM or 0.5 µM Compound E (CompE) or 10 µl
of DMSO as a control. Cells were counted at 24 h intervals for 5 days and the population
doubling times were calculated using GraphPad Prism (v. 4.0). There was an increase in
doubling times for both RPMI-8402 and HPB-ALL upon CompE treatment (Figures 12A
(RPMI-8402) and 12B (HPB-ALL)). For RPMI-8402, there was a 5-9 h increase in
population doubling when treated with CompE. Similar results were seen in the HPBALLs treated with CompE; however the increase in doubling time was much greater (1019 h). Thus, CompE inhibits cell growth, although the magnitude of the observed effect
may be dependent upon other cellular factors. For example, the RPMI-8402 cells have a
mutation in PTEN that likely inactivates the function of this protein. As a result, Akt
activity is expected to be high and to promote cell survival despite the presence of
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Figure 12: Effects of GSI Treatment on Cell Growth
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Cells were seeded at 7.5 x 104 and treated with either 0.5µM or 1.0µM of CompE or an equal volume of
DMSO at time 0h. Cells were counted at 24h intervals with a hemacytometer and Trypan Blue. Growth
was graphed and population doubling times were calculated using GraphPad Prism (v. 4.0) software.
(12A) RPMI-8402 cells, which harbor a PTEN mutation, exhibited an increase in population doubling time
when treated with increasing amounts of CompE. (12B) HPB-ALL cells, which are wild-type for PTEN,
also exhibited an increase in population doubling time when treated with CompE.
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CompE. It is presumed that these cells, and others that have inactivated PTEN, are more
dependent upon Akt for survival than NOTCH1 signaling. Therefore, these cells may be
more resistant to GSI treatment, or experience little negative impact resulting from
CompE treatment.
3.3b Effects of NOTCH1 Inhibition on Key Regulators of the PI3K-Akt/mTOR
Pathway
It has been reported that NOTCH1 can downregulate the expression of PTEN via
HES1 resulting in constitutively active PI3K-Akt signaling166 and activation of mTOR
indirectly by cMYC181, thus promoting cell survival (Figure 4). To further explore the
involvement of NOTCH1 in these two critical cell survival pathways at the level of gene
expression, we treated both Jurkat (mutant PTEN) and HPB-ALL (wild-type PTEN) cells
for 48 h with either 1µM CompE or DMSO, then isolated and reverse transcribed total
RNAs. The cDNAs were mixed with 2X SuperArray RT2 qPCR Master Mix and ddH2O,
and then aliquoted into the appropriate wells of a PI3K-Akt/mTOR SuperArray.
SuperArray real-time PCR analysis was performed on the Light Cycler 480 real-time
PCR machine. Data were analyzed using the ∆∆Ct method. Each cell line was analyzed
in duplicate.
The results suggest that the impact of NOTCH1 inhibition on the PI3K-Akt and
mTOR pathways is highly cell-type dependent (Figure 13A). For example, in Jurkat
cells, NOTCH1 inhibition was associated with significantly decreased expression of
PI3KCA and TSC2. In a ‘normal’ wild-type PTEN cell, a decease in the expression of
any PI3K gene could lead to a decrease in Akt activity. However, since PTEN is
inactivated in the Jurkat cells, this decrease probably had little impact on Akt activity
since it is unable to downregulate this pathway. It is plausible that the various PI3K
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isoforms may share redundant functions and could therefore compensate for loss of one
activity. However, the decrease in TSC2 would likely increase mTOR activity since it is
a negative regulator of mTOR182. This increase would likely be much greater in a PTENnull cell. The inhibition of NOTCH1 in the wild-type PTEN cell line HPB-ALL was
associated with significant decreases in expression of EIF4EBP1, PI3KR2 and RPS6KB1
and significant increases in expression of FOXO1, PI3KCG, PI3KR1 and PTEN (Figure
13A). Real-time qPCR validated these changes in expression for PTEN, PI3KCG and
EIF4EBP1 in HPB-ALL cells (Figure 13B).
3.3c Long-Term Downstream Effects of NOTCH1 Inhibition
A problem with GSIs is that they are not completely specific to NOTCH1 and can
potentially inhibit other targets with transcriptional effects independent of NOTCH1.
Further, it is not entirely certain how stable these agents are under standard culture
conditions.

Accordingly, to better assess the effects of NOTCH1 inhibition on

downstream targets, we knocked down NOTCH1 in Jurkat cells, using shRNA lentiviral
particles specific for NOTCH1. We chose the Jurkat cell line for our studies since these
cells exhibit increased NOTCH1 signaling due to a FBW7 mutation, have inactivated
mutant PTEN and therefore represent a large fraction of T-ALL cases, and are easily
transduced by lentivirus. Stable clones were selected with puromycin and single clones
were isolated following plating in soft agar. RNA and whole cell extracts (WCE) were
prepared to identify clones with decreased expression of NOTCH1. We identified 2
clones in which NOTCH1 was significantly decreased (55% knock down for J.N1KD 2-4
and 79% knock down for J.N1KD 2-7) when compared to the non-targeted clones.
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Figure 13: The Involvement of NOTCH1 in the PI3K-Akt/mTOR Pathways
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RNAs were isolated from Jurkat and HPB-ALL cells treated with either DMSO (control) or 1uM CompE
for 48h. cDNAs were amplified and run on a PI3K-Akt/mTOR SuperArray plate from SA Biosciences that
contained primers for 84 genes most relevant to the pathways. The SuperArray was performed on a
LightCycler 480 real-time PCR machine. (13A) A summary of genes in which there was a significant
(p≤0.05) change in transcript levels when cells were treated with CompE. Expression levels and p-values
in bold depict statistically significant changes. (13B) Real-time PCR was used to validate the expression of
some of the genes of interest in both Jurkat and HPB-ALL cells treated with either DMSO or CompE.
Transcript levels were normalized to h18S.
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Decreased NOTCH1 was verified by real-time qPCR and Western blot analysis
(Figure14).
To examine the impact of loss of NOTCH1 on cell proliferation, non-targeted
control (J.ntc) and NOTCH1 knock down sublines (J.N1KD 2-4 and J.N1KD 2-7) were
seeded at 7.5 x 105 cells/mL in 10 mL of RPMI1640, containing 15% FBS and 0.25
mg/mL puromycin. Cells were counted at 24 h intervals using Trypan blue to stain the
non-viable cells blue and a hemocytometer.

Cell counts were graphed and the

exponential population doubling time was calculated. There was a nominal effect on the
population doubling times between the J.ntc clone (30.46 h) and J.N1KD 2-4 (33.96 h)
and J.N1KD 2-7 (30.68 h) (Figure 15A). Thus, in PTEN deficient Jurkat T-ALL cells,
the loss of NOTCH1 has minimal impact on cell proliferation.
The effects of NOTCH1 inhibition on cell cycle progression and baseline
apoptosis were analyzed using flow cytometery techniques. There was a slight albeit
statistically insignificant increase in the number of cells in the S-phase in J.N1KD 2-4
(23.67%) and J.N1KD 2-7 (22.68%) cells compared to J.ntc (19.8%) cells (Figure 15B).
There was also a slight increase in baseline apoptosis in the NOTCH1 knockdown clones
(24% and 27% for the J.N1KD 2-4 and J.N1KD 2-7, respectively) (Figure 15C).
However, this increase in apoptosis was statistically insignificant. Thus, in the Jurkat TALL model, NOTCH1 inhibition appeared to have little effect on either cell cycle
progression or spontaneous apoptosis. This is likely a unique characteristic of these
PTEN-null T-ALL cells as they are probably more dependent upon Akt for survival as a
result of PTEN inactivation than cells with an intact PTEN.
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Figure 14: Development of NOTCH1 Knockdown Model
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The Jurkat T-ALL cell line, which is PTEN null and has increased NOTCH1 activity as the result of a
mutation in FBW7, was transduced with Lenti-viral particles containing shRNA specific for NOTCH1 or a
non-targeting sequence (ntc). Transduced cells were subjected to puromycin selection and individual
clones were isolated from soft agar. Several clones were analyzed by Western Blot techniques for the
knocked-down expression of ICN. J.N1KD clones 2-4 and 2-7 showed the most reduced expression of
ICN. The reduced expression of ICN in J.N1KD 2-4 and J.N1KD 2-7 were accompanied by a significant
decrease in expression of HES1 and DTX1, both known NOTCH1 target genes. Abbreviations: J, Jurkat;
ntc, J.ntc.
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Figure 15: Effects of NOTCH1 Inhibition on Cell Growth, Cell Cycle Progression
and Apoptosis
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(15A) Cell growth of J.ntc, J.N1KD 2-4 (J.2-4) and J.N1KD 2-7 (J.2-7) was measured with a
hemacytometer and Trypan Blue. Viable cells were counted in triplicate for 5 days and the population
doubling times were calculated. There was no significant difference between the population doubling times
for J.ntc, J.N1KD 2-4 and J.N1KD 2-7. (15B) Inhibition of NOTCH1 has very little effect on cell cycle
progression, as is evident by lack of changed in the percentage of cells retained in each phase of the cell
cycle when comparing the NOTCH1 knock-down clones to J.ntc. (15C) Inhibition of NOTCH1 has a very
modest effect on apoptosis, as evident by the slight increase (24-27%) of AnnexinV+ cells in the NOTCH1
knock-down clones when compared to J.ntc.
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3.3d NOTCH1 Inhibition has No Effect on Chemotherapeutic Response
To determine the impact of loss of NOTCH1 on chemotherapy sensitivity or
resistance, J.ntc, J.N1KD 2-4 and J.N1KD 2-7 were seeded at 4000 cells/well in 96 well
plates and incubated for 4 days with varying concentrations of chemotherapeutic agents,
including methotrexate (MTX), daunorubicin (DNR), VP16 and L-asparaginase (L-ASP).
The cells were exposed to 2.5 mg/mL MTT substrate for 4 h and lysed with 10% SDS in
10 mM HCl overnight. A visible microplate reader was used to read the plates and the
IC50s for each chemotherapeutic agent were calculated graphically using GraphPad Prism
software. Loss of NOTCH1 had very little effect on the IC50 for each agent (Figure 16).
Thus, it appears that in Jurkat cells, loss of NOTCH1 has very little impact on the
chemotherapy sensitivity. This lack of an augmented anti-proliferative effect resulting
from decreased NOTCH1 is likely the result of Jurkat cells being dependent (or maybe
even addicted) to Akt for survival due to the fact that there is an overall lack of PTEN
function, as noted above. I would suspect that if the Jurkat cells were treated with an Akt
inhibitor in combination with these chemotherapeutic agents, the cells would become
more sensitive to the latter, and the IC50s would decrease.
3.3e NOTCH1 Inhibition is Associated with Changes in Cell Surface Marker
Expression
Flow cytometery was used to measure cell surface marker expression as a means
to monitor cell differentiation.

NOTCH1 inhibition was associated with decreased

expression of CD3, CD4, CD5, CD7, CD69, CD95 and CD28 (Figure 17). Decreased
expressions of CD1a, CD4, CD7 and CD3 are signs of an “immature” phenotype
displayed in adult T-ALLs where NOTCH1/FBW7 are wild-type141. Consistent with this,
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Figure 16: Effects of NOTCH1 Inhibition on Chemotherapeutic Response
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Using the MTT assay, the impact of NOTCH1 inhibition on the chemotherapeutic response to single agents
was evaluated. (16A) Response to methotrexate (MTX). (16B) Response to VP-16. (16C) Response to
daunorubicin (DNR). (16D) Response to L-asparaginase (ASP). The IC50 for each agent was calculated
using GraphPad Prism software (v. 4.0). Abbreviations: J.2-4, J.N1KD 2-4; J.2-7, J.N1KD 2-7.
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Figure 17: Effects of NOTCH1 Inhibition on Cell Differentiation
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Cell surface markers that are key indicators of cell differentiation were measured by flow cytometry.
NOTCH1 knock-down was accompanied by a decrease in expression of CD3, CD4, CD5, CD7, CD69 and
CD28.
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in the Jurkat cell line model, NOTCH1 expression is indicative of a more “mature”
phenotype.
3.4 Conclusions
Our studies hint that NOTCH1 signaling may play a more complicated role in the
PI3K-Akt/mTOR pathways than previously considered, and that the impact of NOTCH1
signaling on these pathways may be dependent upon the status of PTEN. Although we
saw alterations in expression of other key PI3K-Akt/mTOR pathway genes, including
some that would increase Akt activity (and thus promote survival) and others that would
downregulate Akt, the composite phenotype would ultimately depend upon the functional
status of PTEN. For example, while NOTCH1 inhibition was associated with a decrease
in expression of PI3KCA in Jurkat cells, this probably wouldn’t have much of an effect
on cell survival since PTEN is non-functional and Akt activity is essentially unregulated.
Likewise, in the HPB-ALL cells, the increased expression of PTEN, due to NOTCH1
inhibition, would likely result in decreased Akt activity, while increased expression of
PI3KCG could possibly promote increased Akt activity and subsequent cell survival.
These effects could impact the response to chemotherapy. For example, an increase in
PTEN expression could lead to chemotherapy sensitivity because it will restrict the
activation of Akt, thus limiting the signals for cell survival. However, an increase in
PI3KCG could lead to chemotherapy resistance because it will increase overall Akt
activity, and thus promote cell survival. Thus, the overall effect on the cell proliferation
and survival would be reflecting a composite phenotype, which may be ultimately
dependent/regulated by the functional status of PTEN.
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In this study, it is evident that NOTCH1 inhibition has very little effect on cell
survival and chemotherapeutic response in T-ALLs that are PTEN null.

This is

supported by the fact that NOTCH1 inhibition was not associated with significant
changes in population doubling time, changes in apoptosis or cell progression, or even in
responses to chemotherapeutic agents. It is likely that our PTEN inactivated model is
addicted to Akt signaling for survival, and that NOTCH1 signaling is dispensable. This
may explain why initial clinical trials with GSIs showed these drugs were at the very
most cytostatic125, 164. The T-ALL patients enrolled in these trials could have easily have
inactive PTEN, either by mutation or posttranslational modifications, as such events can
occur in up to 70% of T-ALLs166,

198

Accordingly, targeting NOTCH1 for T-ALL

therapy would be far more beneficial in T-ALLs in which PTEN is wild-type and active.
Such cells would not be nearly as dependent upon Akt for survival because PTEN is able
to regulate Akt activation, and thus would be more dependent on aberrant NOTCH1
signaling for survival. These studies suggest that PTEN status need to be taken into
consideration when targeting NOTCH1 for therapy, not only its mutational status but its
functional status as well.
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CHAPTER 4
IDENTIFICATION OF NOVEL NOTCH1 TARGETS
4.1 Introduction
Despite the extensive analysis of NOTCH1 during the past 6 years, including the
discovery of NOTCH1 mutations in >50% of T-ALLs, there is surprisingly limited
knowledge of the downstream gene targets of NOTCH1 signaling. NOTCH1 functions
through ICN, which is cleaved during ligand binding by γ-secretase78,

79, 85

.

ICN

translocates to the nucleus, binds to CSL, converting it to a coactivator, and recruits
additional coactivators to initiate transcription of target genes78,

79, 85

. The most well

known transcriptional targets of NOTCH1 include HES1 and HES5, HERP family and
DTX1106-108, all basic helix-loop-helix (bHLH) proteins106-108.

NOTCH1 can also

indirectly regulate the transcription of other target genes through the activities of its own
direct targets. For example, HES1 and HERP proteins negatively regulate the expression
of many downstream target genes, including those involved with apoptosis and
proliferation such as PTEN106,

166

. Other direct or indirect NOTCH1-regulated genes

include p21Cip/Waf235, CD25236, pre-Tα237, cyclin D1238, the proapoptotic receptor
NUR239 and transcription factors of the ΝF-κB family35. cMYC has been identified as a
direct NOTCH1 target, as well103-105. By identifying the downstream transcriptional
targets of NOTCH1 signaling, we can achieve a better understanding of the role of
NOTCH1 in T-ALL and how it may be exploited for new therapeutic advantage.
In a recent study by Buonamici et al.240, a murine model was used to demonstrate
that the oncogenic expression of NOTCH1 (i.e., ICN) could induce the development of
T-ALL and target leukemic cells to the CNS240. They discovered that a number of
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NOTCH1-targeted genes could be regulators of cell adhesion, migration and metastasis,
and could play a significant role in the infiltration of T-ALL cells to the CNS. A gene of
particular interest was CCR7, a chemokine receptor that is a known regulator of
lymphocyte migration241. This gene was significantly upregulated when NOTCH1 was
induced. The expression of CCR7 in T-ALL cell lines was enough to target the cells to
the CNS. It’s unlikely that CCR7 is sufficient alone, but that other factors are also
involved in targeting leukemic cells to the CNS.
The study described in this chapter was designed to expand upon these studies
and to identify novel NOTCH1 downstream targets that have not been previously
reported, in hope that this may better elucidate the relationship between NOTCH1
signaling and disease progression, as well as its relationship to chemotherapy sensitivity.
4.2 Materials and Methods
4.2a Microarray and Validation
RNAs were isolated from Jurkat T-ALL cells that were transduced with shRNA
particles to knock down the expression of NOTCH1 using the TRIzol ® protocol (see
Chapter 3). A quality check of the total RNA was performed using an Agilent 2100
Bioanalyzer (Agilent Technologies; Palo Alto, CA) to determine if the 18S and 28S
ribosomal bands were defined and to ensure no RNA degradation had occurred.
Aminoallyl-aRNA was produced with 500 ng of total RNA and TargetAMP1-Round
Amnoallyl-aRNA Amplification Kit 101 (Epicentre; Madison, WI). First strand cDNA
synthesis used oligo(dT) primers containing a phage T7 RNA polymerase promoter
sequence (Invitrogen). Second strand cDNA synthesis and in vitro transcription were
generated with the UTP nucleotide is partially substituted with an aminoallyl-UTP.
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Aminoallyl-aRNA was purified using Qiagen RNeasy mini kit (Qiagen) and the
concentration was determined using a NanoDrop ND-1000.
Alexa fluor Reactive Dyes Alexa 555 or Alexa 647 (Molecular Probes; Eugene,
OR) was used to label 5 µg of each Aminoallyl-aRNA. The samples were incubated with
the dye for 30 min at room temperature, and run through another RNeasy column to
remove any unincorporated dye.

The samples were quantitated on a NanoDrop

spectrophotometer. The Agilent 60-mer microarray (Whole Human Genome Arrays
4x44K p/n G4112F) processing protocol was followed. Briefly, 0.825 µg of Alexa 555labeled Aminoallyl-aRNA and 0.825µg of Alexa 647-labeled Aminoallyl-aRNA were
mixed together and allowed to co-hybridize on the array for 17 h at 65°C. Agilent’s
SureHyb hybridization chambers were used to allow complete mixing of the
hybridization solution in a rotation rack in a hybridization oven.

Following

hybridization, the slides were washed according to Agilent’s protocol.
Slides were immediately scanned with the Agilent dual laser scanner. The photo
multiplier tube (PMT) setting with extended dynamic range was at Hi 100% and Lo 10%
for the red and green channels. Tiff images were analyzed using Agilent’s feature
extraction software to obtain fluorescent intensities for each spot on the arrays. Linear
and LOWESS normalization was performed on the intensity values.
Changes in gene expression were validated by real-time qPCR. Total RNAs were
isolated using the TRIzol® protocol. cDNAs were amplified using random hexamer
primers and real-time qPCR was used to quantitate transcript levels. Changes in gene
expression levels were calculated using the ∆∆Cp method.
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4.2b microRNA Array and Validation
Agilent’s miRNA arrays were processed using the miRNA Microarray System
protocol (Agilent).

Each Human miRNA Microarray V2 slide contained 8 miRNA

arrays. Each array consisted of human (n=732) and human viral microRNAs from the
Sanger miRBASE 10.1. Agilent’s “miRNA Microarray System” protocol (v.1.5) was
followed during miRNA labeling and array hybridization. Briefly, each total RNA was
analyzed with Agilent 2100 Bioanalyzer. Total RNA (100 ng) underwent phosphatase
treatment using calf intestine alkaline phosphatase (GE Healthcare Bio-Sciences Corp,;
Piscataway, NJ) at 37°C for 30 min. The samples were then denatured and labeled by
ligation of one cyanine 3-pCp molecule to the 3’ end of the RNA molecule. The samples
were incubated at 16°C for 2 h to permit ligation. The labeled miRNAs were cleaned up
using Micro Bio-Spin 6 columns (Bio-Rad Laboratories). The samples were dried in a
speed-vac and then resuspended in 18µl of nuclease-free water, in which 4.5 µl of 10X
GE Blocking and 22.5 µl of 2XHi-RPM Hybridization Buffers (Agilent) were added and
incubated at 100°C for 5 min, followed by cooling on ice for 5 min. Samples were
immediately added to the array in an Agilent SureHyb Hybridization chamber. The
chambers were rotated at 20 rpm in a hybridization oven for 20 h at 55°C.
Following hybridization, the slides were removed from the chamber and washed
in GE Wash Buffer 1 for 5 min and pre-warmed 37°C GE Wash Buffer 2 for 5 min
(Agilent). The slides were removed from Wash Buffer 2 and allowed to dry, and then
scanned using the Agilent dual laser scanner. The PMT settings are set at 100% and 5%
for the green channel.
software.

Tiff images are analyzed using Agilent’s feature extraction
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The relative expression level of each microRNA (miR) was validated with
Applied Biosystems TaqMan® MicroRNA Assays (Applied Biosystems). Total RNAs,
including miRs, were isolated using the TRIzol® protocol. Each RNA sample was
reversed transcribed with a master mix consisting of 100 mM dNTPs, MultiScribe
Reverse Transcriptase (50 U/µL), 10X RT Buffer and RNase Inhibitor. This master mix
was aliquoted to the appropriate number of PCR tubes and an RT primer was added.
Each primer was specific for a miR of interest. RTs were amplified with a thermocycler.
Each miR was quantitated using a Light Cycler 480 (Roche) and each RNA and primer
combination was quantitated in triplicate. The Light Cycler master mix consisted of
TaqMan 2X Universal PCR Master Mix, without AmpErase and nuclease-free water.
This master mix was aliquoted and 20X TaqMan MicroRNA assay mix was added, along
with the RT product. This final master mix was aliquoted into 3 wells of a 96-well plate.
The fold changes for each miR were calculated by the ∆∆Cp method.
4.3 Results
4.3a Microarray Results
In 2009, Chadwick et al. prepared RNA from Jurkat cells that were retrovirally
transduced with constitutively active forms of NOTCH1 and used Affymetrix microarray
analysis to identify novel NOTCH1 gene targets242. They identified several genes that
appeared to be regulated by NOTCH1, including IGF1R, CD28 and HERP2. In a further
attempt to identify novel NOTCH1 target genes, we isolated total RNAs from the J.ntc,
J.N1KD 2-4 and J.N1KD 2-7 sublines and analyzed differentially expressed genes with
an Agilent Human Whole Genome Oligonucleotide array. Over 1200 genes showed
differential expression between the non-targeted control Jurkat cells and the two
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NOTCH1 knockeddown Jurkat clones (cutoff was a 1.5-fold change in expression with
p≤0.05). There was a 20- to 40-fold decrease in expression of the well known NOTCH1
target gene HES1, and an 11-fold decrease in expression of DTX1 in the NOTCH1
knocked-down clones (Figure 18A). There was some agreement in the differentially
expressed gene targets identified on our microarray and those from the Chadwick study,
including EFEMP1, RANBP2, GIMAP5, SHQ1, IGF1R, BMP2K and CD28 (Figure
18A). Other differentially expressed genes of interest from the microarray included IL7R, a documented NOTCH1 target gene243, DR4, TGFβ1, PI3KR2, IGF1R and Rictor
(Figure 18A). The expression of all of these genes, except for Rictor, was decreased
upon knockdown of NOTCH1. Real-time qPCR was able to validate the association of
NOTCH1 inhibition with the decreased expression of established NOTCH1 targets
including DTX, HES1, and IL7R, along with decreased TGFβ1 and with increased Rictor
(Figure 18B).
Rictor forms a complex with mTOR2, which can promote cell survival thorough
the phosphorylation and complete activation of Akt (phosphorylation occurs on S473)182.
Concurrent with the real-time data, western blot analysis shows an increase in Rictor
protein levels and increased pAKT S473 (Figure 18C). The promoter for Rictor was
identified using genomic sequence approximately 2.0kb from the atg translation start site
for the Rictor coding sequence and Genomatix software.

Genomatix predicted the

promoter (632bp) to lie with the 2.0kb genomic sequence.

Matinspector software

identified both NOTCH1 indirect (via CSL; a.k.a. RBPJκ) and HES1 binding sequences
within the Rictor promoter sequence.
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Figure 18: Identification of Novel NOTCH1 Downstream Targets
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18C:

Total RNA was isolated from J.ntc, J.N1KD 2-4
and J.N1KD 2-7 and differentially expressed genes determined on an Agilent Human Whole Genome
Oligonucleotide array. The cutoff limit was at least a 1.5-fold change in expression in conjunction with
p≤0.05. (18A) Summary of the change in expression of known NOTCH1 target genes, potential NOTCH1
target genes previously identified by Chadwick et al and novel NOTCH1 target genes that appear
interesting and relevant. (18B) Real-time RT-PCR validation of novel NOTCH1 target genes. (18C)
Western blot analysis of Rictor expression in J.ntc, J.N1KD 2-4 and J.N1KD 2-7.
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Figure 19: NOTCH1 Inhibition is Associated with the Significant Change in
Expression of 20 miRs
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Total RNAs were isolated from J.ntc, J.N1KD 2-4 and J.N1KD 2-7 and used determinations of
differentially expressed miRNAs on an Agilent Human microRNA Version 2 array. The expression of 732
human miRs were determined. The cutoff limit was 1.5-fold change in expression accompanied by p≤0.05.
A significant change in expression for 20 miRs was observed between J.ntc and the 2 NOTCH1 knockdown clones (Top Panel). Of the 20 miRs, 2 were of particular interest because they are polycistronic and
believed to share a common promoter (Bottom Panel).
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4.3b Potential microRNA Targets of NOTCH1
To identify potential miRNAs regulated by NOTCH1, total RNAs were isolated
from J.ntc, J.N1KD 2-4 and J.N1KD 2-7 cells and analyzed on an Agilent Human
microRNA V2 array, encompassing 732 human microRNAs (miRs). Knockdown of
NOTCH1 was associated with a change in expression of twenty miRs (cutoff was 1.5fold and p≤0.05; Figure 19). This suggests that several miRs may be downstream targets
of NOTCH1. Of the 20 miRs that showed the differential levels between the nontargeted control and knockdown cell lines, the three most significant changes were for
hsa-Let-7e, hsa-miR-99b and hsa-miR-125a-5p.

These miRs are believed to be

polycistronic, transcribed from the same promoter, and therefore share the same pritranscript.
Differential expression of mature hsa-Let-7e, hsa-miR-125a-5p and hsa-miR-99b
was further tested using TaqMan microRNA assay probes, with the original RNAs used
for the microarray and with additional RNA isolations (Figure 20A (original array RNA)
and 20B (additional RNA isolation)). Significantly decreased hsa-miR-125a-5p and hsamiR-99b was seen in both RNA preparations for the knockdown cell lines compared to
the non-targeted control cell line. A decrease in miR expression was also seen in Jurkat
cells that were treated with the GSI CompE (Figure 20C). Unexpectedly, hsa-Let-7e
expression did not adhere to the same expression pattern as hsa-miR-125a-5p and hsamiR-99b.

Although its expression was significantly decreased when NOTCH1 was

inhibited on the original microRNA array, it failed to validate with the TaqMan
microRNA assays.

If hsa-Let-7e, hsa-miR-125a-5p and hsa-miR-99b are truly

polycistronic, we would have expected the expression of all 3 miRs to decrease upon
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Figure 20: Validation of miRs Let-7e, 125a-5p and 99b Upon NOTCH1 Inhibition
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Expression of mature hsa-Let-7e, hsa-miR-125a-5p and hsa-miR-99b were validated using TaqMan
microRNA assays from Applied Biosystems. The mature transcript of each miR was quantitated by realtime qPCR using miR-specific probes. We validated miR expression in both the original RNAs used for
the initial microRNA array (16A) and subsequent RNA isolations from J.ntc, J.N1KD 2-4 and J.N1KD 2-7
(16B). Jurkat cells were treated with either DMSO or 1uM of CompE for 4-7 days, and miR expression
levels were measured to validate the results seen with J.ntc, J.N1KD 2-4 and J.N1KD 2-7 (16C). A timedependent decrease in the expression of -miR-125a-5p and hsa-miR-99b was seen upon NOTCH1
pharmaceutical inhibition.
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NOTCH1 inhibition. We suspect that hsa-Let-7e may undergo additional regulation,
independent of hsa-miR-125a-5p and hsa-miR-99b. While these results strongly suggest
that levels of hsa-miR-125a-5p and hsa-miR-99b are bona fide downstream targets of
NOTCH1, the mechanism is unclear; i.e., regulation may be direct or indirect. Future
studies will focus on identifying and amplifying the promoter with 5’RACE, and to
address NOTCH1 involvement with reporter gene assays.

These studies will also

identify and validate the downstream targets of these 2 miRs as well, and to role T-ALL
progression and chemotherapy response.
4.4 Conclusions
Our studies have identified three potential novel targets of NOTCH1 signaling.
The first target is Rictor. It appears that NOTCH1 signaling represses the expression of
Rictor because upon NOTCH1 shRNA knockdown there was a significant increase in the
expression of this critical gene, at both the transcript and protein levels. This increase in
Rictor would likely lead to increased Akt phosphorylation at S473, thus promoting cell
survival signals173. These findings suggest some caution should be exercised when
attempting to inhibit NOTCH1 with GSIs in T-ALL therapy, especially in T-ALLs, for
which PTEN is frequently inactivated by mutation or posttranslational modification and
activation of Akt is unregulated. Thus, inhibition of NOTCH1 with small molecule GSIs
may need to be combined with an Akt inhibitor to disrupt Akt signaling or perhaps with
rapamycin to potentially inhibit mTOR2 activity172.

To date, there are no specific

inhibitors of mTOR2. However, rapamycin has been shown to inhibit mTOR1 and in
some cases mTOR2 in a cell context-dependent manner172.
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The other two new targets of NOTCH1 signaling identified in our study are hsamiR-125a-5p and hsa-miR-99b.

Our data suggest that NOTCH1 can promote the

expression of miRs-125a-5p/99b because when NOTCH1 is inhibited by shRNA
knockdown or GSI treatment, there is a significant decrease in expression of these two
miRs.

The implications for the impact of miRs on chemotherapy have yet to be

determined.
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CHAPTER 5
CONCLUSIONS
A major confounding problem in the biology and therapy of pediatric T-ALL has
been determining the prognostic value of NOTCH1 mutations.

In our studies, we

attempted shed important new light on this question. We confirmed the presence of high
frequency mutations in NOTCH1 and FBW7 in our cohort of 47 T-ALL specimens and
we were the first to suggest that PTEN is much more frequently mutated in primary TALL specimens than originally believed. However, in our cohort of pediatric T-ALLs,
we also found absolutely no association between NOTCH1 mutations, alone or in
combination with FBW7 and/or PTEN, and treatment outcome.

This result is in

agreement with those in a report published by van Grotel et al.135.
Upon further review of our findings, this may not be that surprising after all.
Ultimately, the underlying biology of the disease determines how a patient is going to
respond to therapy. NOTCH1 mutations can be found in patients generally considered to
be both “good responders” to therapy (low to undetectable MRD levels following
induction therapy) and “poor responders” (detectable MRD levels following induction
therapy). Likewise, NOTCH1 mutations can be found in patients who are classically
defined into low, standard and high risk of relapse.

Thus, the prognostic merit of

NOTCH1 mutations in this disease may be dependent in large part on the chemotherapy
regimen that is administered to the patient.

Supporting this notion, our studies

demonstrated that several chemotherapy relevant genes may be potential direct or indirect
downstream targets of NOTCH1 signaling. These genes encoded drug efflux pumps that
would likely render cells more chemotherapy resistant (i.e., MDR1, ABCC5) and others
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that could render cells more chemotherapy sensitive (i.e., hRFC). The overall net effect
of these genes can significantly impact net chemotherapeutic response, depending upon
types and doses of drugs used.
We saw evidence of this in our analysis of NOTCH1 mutations. Overall, within
our cohort, NOTCH1 mutations were present in 39% of the patients who relapsed and
29% of the patients who responded to therapy, independent of the chemotherapy protocol
used. When this analysis was restricted to patients treated with a single chemotherapy
regimen, by focusing only on the patients treated with POG8704, we saw a marked
decrease in the frequency of mutations in patients who relapsed (21.4%) compared to
those who responded to treatment (42.9%).

However, this decrease in mutation

frequency was not statistically significant.
We contend that it is unlikely that the presence of NOTCH1 mutations alone is
enough to predict treatment outcome, as not all NOTCH1 mutations are activating to the
same degree. On this basis, it seems more likely than not that the overall level of
NOTCH1 signaling, as reflected in levels of NOTCH1 targets such as HES1, could be
prognostically important. This is also supported in a recent report by Rao et al.244, in
which they used the average expression value of 10 known NOTCH1 target genes
(NOTCH10) to predict GSI sensitivity244. The use of such a “gene signature” profile,
such as NOTCH10, will take into account all factors that regulate the potency of the
NOTCH1 signal, including ligand activation and protein turnover regulated by the E3
ubiquitin ligases, such as Numb and FBW7.
To better study the prognostic value of NOTCH1 mutations in T-ALL, the
composition of the study population also needs to be carefully controlled. For example,
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if the patient cohort contains mostly good responders, NOTCH1 mutations will
undoubtedly be associated with favorable outcomes. Likewise, if the cohort contains
mainly poor responders, NOTCH1 mutations will be associated with poor outcomes.
Clearly, a carefully crafted study design will be important for finally answering this
important question.
Although NOTCH1 mutations may not necessarily be prognostic, NOTCH1
remains an attractive and potentially useful therapeutic target for T-ALL. In many cases,
mutations in NOTCH1 increase the activity of the receptor, even constitutively in some
instances, either by increasing its susceptibility to γ-secretase cleavage in the absence of
ligand or by inhibiting the ubiquitination and turnover of ICN125. The activation of
NOTCH1 can be blocked with the use of GSIs, which prevents the cleavage of ICN.
Although GSIs have failed miserably in clinical trials, they should not be completely
abandoned160, 161. Recent studies have been able to optimize GSI doses without causing
much gastrointestinal toxicity169, 170. With that being said, GSIs may not be beneficial to
every T-ALL patient with NOTCH1 mutations. Indeed, GSIs are likely to be effective in
those T-ALLs that are completely dependent upon NOTCH1 for survival. This was
evident in our J.N1KD cell line models, for which significantly decreased NOTCH1
levels had little effect on cell survival. We suspect this is due to the fact that Jurkat cells
harbor a PTEN mutation that causes the loss of PTEN expression. As a result, these cells
(and likely a substantial number of T-ALLs, overall) have lost functional PTEN and are
highly dependent upon Akt for survival. Thus, T-ALL patients should be thoroughly
screened for mutations other than NOTCH1 that may contribute to the overall cell
survival before GSIs are given.
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As noted above, our study is the first to report such a high frequency of PTEN
mutations in T-ALL (~60% as compared to 17%166). Whether this is just a unique feature
of our patient cohort or is a more common occurrence in T-ALL still needs to be
determined. It is assumed that such mutations would inactivate PTEN, or at the very
least diminish its function. Our findings, in combination with those of Silva et al. that
PTEN is frequently posttranslationally inactivated in up to 70% of T-ALLs198 suggests
that PTEN plays a far more important role in the biology and therapy of T-ALL than
previously considered. Indeed, it seems likely that the vast majority of T-ALLs have
non-functional PTEN protein and are generally “addicted” to Akt signaling for survival.
It is suspected that this addiction can lead to chemotherapy resistance, as unregulated Akt
activity promotes cell growth and survival. In these T-ALLs, combinational therapies that
employ the use of Akt inhibitors and agents that target the downstream events of Akt may
be beneficial. More studies are needed to understand the essential requirements of TALL survival and resistance mechanisms so that more targeted therapies can be
developed.
Lastly, our study highlights the urgent need for more sophisticated studies that
focus on the biology of relapse. Relapse remains the number one cause of treatment
failure. By better understanding the mechanism of relapse, and identifying common traits
that are unique to relapsed T-ALL clones, we may be able to tailor therapies to prevent
chemoresistance in these clones. Likewise, if we can identify genetic alterations that are
required for relapse, we may also be able to develop targeted therapies for relapsed
disease, as well. Of course, such studies may prove difficult since T-ALL in children is a
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comparatively rare disease with too few cases to effectively evaluate therapies and
research.
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T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% of pediatric ALL
cases and is associated with early relapse and inferior outcome. The poorer prognosis of
T-ALL compared to B-precursor ALL may in part reflect the lack of unique features on
which to base therapy. NOTCH1 mutations are of particular interest since these were
reported in 37-71% of T-ALLs. The prognostic value of NOTCH1 mutations remains
controversial as both favorable and unfavorable associations were reported, whereas in
other studies, there were no associations between NOTCH1 mutations and treatment
outcome. We explored the impact of mutations in NOTCH1, FBW7 and PTEN on
prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia.
We identified a high frequency of mutations in NOTCH1 (16 patients), FBW7 (5
patients) and PTEN (26 patients) in a well defined cohort of 47 pediatric T-ALL
specimens. NOTCH1 mutations showed a 1.3-3.3-fold increase in activation over wildtype NOTCH1 in reporter assays; mutant FBW7 resulted in further augmentation of
NOTCH1 activity. NOTCH1 and FBW7 mutations were accompanied by increases in
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median transcripts for NOTCH1 target genes (HES1, DELTEX1 and cMYC). However,
none of these mutations were associated with treatment outcome.

Increased HES1,

DELTEX1 and cMYC transcript levels were associated with significant increases in the
transcript levels of several chemotherapy relevant genes, including MDR1, ABCC5,
reduced folate carrier, asparagine synthetase, thiopurine methyltransferase, Bcl-2 and
dihydrofolate reductase. Our results suggest (1) multiple factors should be considered
with attempting to identify molecular-based prognostic factors for pediatric T-ALL and
(2) that, depending on the NOTCH1 signaling status, modifications in the types or dosing
of standard chemotherapy drugs for T-ALL, or combinations of agents capable of
targeting NOTCH1, AKT and/or mTOR with standard chemotherapy agents may be
warranted.
Relapse is the most common caused of off-therapy events and is responsible for
the majority of ALL treatment failures. Relapse can arise from the (i) the induction of
resistance via acquisition of new genetic alterations after diagnosis, (ii) the selection and
expansion of an already present resistant-subpopulation at the time of diagnosis, or very
rarely as (iii) a secondary, de novo ALL. To determine the contribution of genetic
alteration to the development of relapse in T-ALL, we assessed the frequency of
mutations in NOTCH1 alone or in combination with mutations in FBW7 and PTEN at the
time of diagnosis and relapse in 11 paired clinical T-ALL specimens. We observed that
the 7 patients harboring mutations in NOTCH1 and/or PTEN at some stage in their
disease had a longer remission period (13 months vs. 5.5 months), and were typically
diagnosed at an early age (120 months vs. 132 months). In these 7 patients, nearly 70%
of relapse appeared to be associated with the emergence of a new leukemic clone, an
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assumption made by the presence of a new mutation or loss of a mutation at relapse.
Using real-time PCR techniques with specific hybridization probes, we were able to
determine that the leukemic clone for one patient was present at the time of diagnosis, but
at a very low expression level. This suggests that the clone responsible for relapse was
resistant to the initial chemotherapy treatment. For another patient, the relapse clone
could not be detected at diagnosis, suggesting that it was induced following
chemotherapy. This study strongly warrants future studies with a larger patient cohort to
systematically identify specific hallmarks of relapse.
NOTCH1 is a potentially attractive therapeutic target for T-ALL since
constitutively activating effects of mutant NOTCH1 can be abolished with γ-secretase
inhibitors (GSIs). Because of possible effects of GSIs on other cellular targets in addition
to NOTCH1, we explored shRNA knockdown of NOTCH1 to identify novel NOTCH1regulated genes that may serve as prognostic indicators or therapeutic targets in T-ALL.
NOTCH1 expression was knockeddown in Jurkat T-ALL cells using lentivirus
expressing shRNAs for NOTCH1 or a non-targeted control (J.ntc) sequence. NOTCH1
knockdown was verified using western blots to measure activated NOTCH1 (ICN1)
protein levels, and real-time RT-PCR to measure transcript levels of known NOTCH1
targets (e.g., HES1). Two clonal sublines (J.N1KD 2-4 and J.N1KD 2-7) were identified
with significantly decreased expression of NOTCH1 compared to J.ntc. The J.N1KD 2-4
and J.N1KD 2-7 sublines showed minimal changes in cell growth, cell cycle progression
and apoptosis. To characterize genotypic changes accompanying NOTCH1 knockdown,
we performed microarray analysis with Agilent Whole Genome oligonucleotide
microarrays and microRNA (miR) HumanV2 arrays. The microarray identified Rictor, a
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key component to in the mTOR2 complex, as a novel downstream target of NOTCH1
signaling.

Upon NOTCH1 inhibition, an increase in the expression of Rictor was

observed, both at the transcript and protein levels. Initial computational analysis of the
Rictor promoter suggests that NOTCH1 may regulate its expression directly (via RBPJκ)
or indirectly (via HES1). The miR array identified 20 miRs in J.N1KD 2-4 and J.N1KD
2-7 cells with altered expression compared to J.ntc greater than 1.5-fold (p<0.05) and
ranging from 3-to10-fold.

miRs hsa-Let-7e, hsa-miR-125a-5p and hsa-miR-99b,

reportedly derived from a polycistronic transcript, were decreased 10-fold accompanying
NOTCH1 knockdown. Using miR qPCR, we confirmed decreased levels of hsa-miR125a-5p and hsa-miR-99b in the J.N1KD 2-4 and J.N1KD 2-7 sublines. In conclusion,
we have developed novel T-ALL cell line models to study the impact of decreased
NOTCH1 levels and activity independent of GSI treatment. Our results implicate
NOTCH1 in regulating levels of Rictor and hsa-miR-125a-5p, and suggest that caution
may be warranted in targeting NOTCH1 with GSIs in the therapy of T-ALL, reflecting
the potential promotion of cell survival via the upregulation of Rictor. The downstream
effect of regulating hsa-miR-125a-5p has yet to be determined.
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